

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Incident falls are strongly associated with subsequent fracture risk in patients attending the FLS after an index fracture: a 3-year prospective cohort study.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-058983
Article Type:	Original research
Date Submitted by the Author:	27-Nov-2021
Complete List of Authors:	<p>Vranken, Lisanne; VieCuri Medical Centre, Department of Internal Medicine; Maastricht University Medical Centre+, Department of Internal Medicine, Research School NUTRIM</p> <p>Wyers, Caroline; VieCuri Medical Centre, Department of Internal Medicine; Maastricht University Medical Centre+, Department of Internal Medicine, Research School NUTRIM</p> <p>Van der Velde, R.Y.; VieCuri Medical Centre, Department of Internal Medicine; Maastricht University Medical Centre+, Department of Internal Medicine, Research School NUTRIM</p> <p>Janzing, Heinrich M. J.; VieCuri Medical Centre, Department of Surgery</p> <p>Kaarsemakers, S.; VieCuri Medical Centre, Department of Orthopedic Surgery</p> <p>Driessen, Johanna; Maastricht University Medical Centre+, Department of Clinical Pharmacy and Toxicology; Maastricht University, Department of Clinical Pharmacy and Toxicology</p> <p>Eisman, John; Garvan Institute of Medical Research, Osteoporosis and bone biology; The University of Notre Dame Australia, School of Medicine Sydney</p> <p>Center, Jacqueline; Garvan Institute of Medical Research, Osteoporosis and bone biology; UNSW, School of Population Health</p> <p>Nguyen, T.V.; Garvan Institute of Medical Research; UNSW, School of Population, Faculty of Medicine</p> <p>Tran, Thach; Garvan Institute of Medical Research, Bone Biology Division</p> <p>Bliuc, Dana; Garvan Institute of Medical Research, Bone and Mineral Research Program</p> <p>Geusens, Piet; Maastricht Universitair Medisch Centrum+, Department of Internal Medicine, Subdivision Rheumatology; Maastricht University, CAPHRI School for Public Health and Primary Care</p> <p>van den Bergh, Joop; Maastricht Universitair Medisch Centrum+, Department of Internal Medicine, Research School NUTRIM; VieCuri Medisch Centrum, Department of Internal Medicine</p>
Keywords:	INTERNAL MEDICINE, Orthopaedic & trauma surgery < SURGERY, GENERAL MEDICINE (see Internal Medicine)



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Incident falls are strongly associated with subsequent fracture risk in patients**  
4 **attending the FLS after an index fracture: a 3-year prospective cohort study.**  
5  
6  
7  
8  
9

10 L. Vranken <sup>1,2,3</sup>, C.E. Wyers <sup>1,2,3</sup>, R.Y. Van der Velde <sup>1,2,3</sup>, H.M.J. Janzing <sup>4</sup>, S. Kaarsemakers <sup>5</sup>,  
11 J.H.M. Driessen <sup>6,7</sup>, J.A. Eisman <sup>8,9,10</sup>, J.R. Center <sup>8,10</sup>, T.V. Nguyen <sup>8,10,11</sup>, T. Tran <sup>8</sup>, D. Bliuc <sup>8</sup>,  
12 P.P.M.M. Geusens <sup>12,13,14</sup>, J.P.W. Van den Bergh <sup>1,2,3,14,\*</sup>  
13  
14  
15  
16  
17  
18  
19

- 20 1. Department of Internal Medicine, VieCuri Medical Center, Venlo, The Netherlands  
21  
22 2. Department of Internal Medicine, Maastricht University Medical Center +,  
23 Maastricht, The Netherlands  
24  
25 3. NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht  
26 University, Maastricht, The Netherlands  
27  
28 4. Department of Surgery, VieCuri Medical Center, Venlo, The Netherlands  
29  
30 5. Department of Orthopedic Surgery, VieCuri Medical Center, Venlo, The Netherlands  
31  
32 6. Department of Clinical Pharmacy and Toxicology, NUTRIM School of Nutrition and  
33 Translational Research in Metabolism, CARIM School for Cardiovascular Disease,  
34 Maastricht University Medical Center +, P.O. Box 5800, 6202 AZ Maastricht, The  
35 Netherlands  
36  
37 7. Department of Clinical Pharmacy and Toxicology, CAPHRI School for Public Health  
38 and Primary Care, Maastricht University, Maastricht, The Netherlands  
39  
40 8. Osteoporosis and Bone Biology, Garvan Institute of Medical Research, Sydney,  
41 Australia  
42  
43 9. School of Medicine Sydney, University of Notre Dame Australia, Sydney, Australia  
44  
45 10. School of Population Health, Faculty of Medicine, UNSW Sydney, Sydney, Australia  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 11. School of Biomedical Engineering, University of Technology Sydney, Sydney,  
4  
5 Australia  
6  
7  
8 12. CAPHRI School for Public Health and Primary Care, Maastricht University,  
9  
10 Maastricht, The Netherlands  
11  
12 13. Department of Internal Medicine, Subdivision Rheumatology, Maastricht University  
13  
14 Medical Center +, Maastricht, The Netherlands  
15  
16  
17 14. Faculty of Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium  
18  
19 \* Corresponding author  
20  
21  
22  
23  
24  
25

### Corresponding author

26 Name: J.P.W. van den Bergh

27  
28 Postal address: Tegelseweg 210, 5912 BL Venlo

29  
30 E-mail: j@vdbergh.org

31  
32 Telephone: 0031-773205555

33  
34 Fax numbers: 0031-773206279  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

### Objectives:

Falls are a strong risk factor for fractures, independent of bone mineral density (BMD) and clinical risk factors. The aim of this study was to evaluate the risk of subsequent fractures in patients who attended the Fracture Liaison Service (FLS), with and without incident falls after the index fracture.

### Method:

A 3-year prospective observational cohort study was conducted in patients aged 50+ years with a recent clinical fracture, starting at the time they attended the FLS. Patients were treated with anti-osteoporosis medication according to the Dutch osteoporosis guideline. Falls were recorded weekly in fall diaries. Subsequent fractures were recorded in fall diaries and annual questionnaires and were radiologically confirmed. The Cox's proportional hazards model was employed to estimate the association between fall and fracture risk, adjusted for predefined covariates including age, gender, index fracture type, BMD, and prevalent vertebral fractures status.

### Results:

The study included 488 patients (71.9% women, mean age  $64.6 \pm 8.6$  years). During the 3-year follow-up, 959 falls had been ascertained in 296 (60.7%) patients (*i.e.*, fallers), and 60 subsequent fractures were ascertained in 53 (10.9%) patients. Of the fractures, 47 (78.3%) were fall-related, of which 25 (53.2%) were sustained at the first fall incident at a median of 34 weeks. An incident fall was associated with an approximately 9-fold (hazard ratio 8.6; 95% CI, 3.1 to 23.8) increase in the risk of subsequent fractures.

### Conclusion:

These data suggest that subsequent fractures among patients on treatment prescribed in a FLS setting are common, and an incident falls is a strong predictor of subsequent

1  
2  
3 fracture risk, and that immediate attention for fall risk could be beneficial in an FLS  
4  
5 model of care.  
6  
7  
8  
9

### 10 **Strengths and limitations**

- 12 - Although this is one of the largest prospective studies in a FLS population  
13 focusing on the incidence of falls after an index fracture, the number of patients is  
14 modest, and the number of subsequent fractures relatively small.  
15  
16  
17  
18
- 19 - Data on falls were collected prospectively using fall diaries. However, no  
20 procedures were in place to validate self-reported falls.  
21  
22  
23
- 24 - No information was available on falls between the index fracture and enrollment  
25 in the study.  
26  
27  
28
- 29 - Relatively healthy patients participated in the study, which may have resulted in  
30 an underestimation of incident falls and subsequent fractures.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Introduction

Patients with a recent fracture have a high imminent risk of subsequent fractures as shown after most fractures<sup>(1-6)</sup>, and a high risk of subsequent falls, as shown after a recent hip fracture<sup>(7-11)</sup>. The Fracture Liaison Service (FLS) is considered the most effective organizational approach for secondary fracture prevention in patients after the age of 50 years with a recent fracture.

Most fractures are caused by a fall, but most falls do not result in a fracture<sup>(12,13)</sup>. Falls are a major contributing factor to the occurrence of fractures, independent and additive to the risk attributable to age and bone mineral density (BMD)<sup>(14-17)</sup>. Guidelines on the FLS therefore recommend fall prevention and prescription of anti-osteoporosis medication (AOM) in high risk patients<sup>(18-22)</sup>. However, it is not well known to what extent the imminent risk of subsequent fractures after an index fracture can be attributed to incident falls. We hypothesized that the risk of subsequent fractures would be substantially higher in patients with falls after a recent fracture than in those without falls. The aim of this study was therefore to evaluate the incidence of falls and subsequent fractures, and the risk of subsequent fractures in those with and without falls after a recent index fracture in patients who attend the FLS.

## Methods

### *Study population and design*

A 3-year prospective observational cohort study was conducted including 500 consecutive patients aged between 50 and 90 years with a recent, radiologically confirmed clinical vertebral or non-vertebral low-trauma fracture, and who were willing and able to participate. Patients were recruited at the FLS in VieCuri Medical Center, Venlo, The Netherlands.

1  
2 Low-trauma fractures were defined as fractures that resulted from a fall from standing  
3  
4 height or less. Excluded were non-Caucasian patients, patients with bone metastasis,  
5  
6 failure of prosthesis or osteomyelitis, and patients with cognitive impairment.  
7  
8

9 According to standard care, a nurse specialized in osteoporosis invited all  
10  
11 patients aged 50 year and older, who visited the emergency department because of a  
12  
13 recent clinical vertebral or non-vertebral fracture, to the FLS. All patients who  
14  
15 responded and agreed to be evaluated were scheduled an appointment for fracture risk  
16  
17 evaluation. Fracture risk evaluation included a detailed questionnaire for evaluation of  
18  
19 risk factors for fractures and falls, including medical history and medication use. Also,  
20  
21 height and weight were measured, a bone mineral density (BMD) measurement with  
22  
23 dual-energy X-ray absorptiometry (DXA) of the lumbar spine, total hip, and femoral  
24  
25 neck, with vertebral fracture assessment (VFA) was performed, and a blood sample was  
26  
27 collected to detect contributors to secondary osteoporosis and metabolic bone disease  
28  
29 (23). According to the Dutch osteoporosis guideline (24), AOM was started in patients with  
30  
31 osteoporosis or having at least one moderate to severe prevalent vertebral fracture  
32  
33 according to Genant et al. (25). Bisphosphonates and denosumab were first-choice  
34  
35 treatments. Teriparatide was restricted to patients already on another AOM with at least  
36  
37 3 fractures, of which 2 were vertebral fractures.  
38  
39  
40  
41  
42  
43

44 The study protocol (registration number NL45707.072.13) was approved by an  
45  
46 independent Medical Ethics Committee and complied with the Declaration of Helsinki.  
47  
48 All patients gave written informed consent prior to participation.  
49  
50  
51

### 52 53 ***Falls and subsequent fractures*** 54

55 During the 3-year follow-up, patients were requested to record falls weekly in a  
56  
57 fall diary. Fall registration started at the beginning of the study, mean  $3.5 \pm 1.0$  months  
58  
59 after the index fracture. A fall was defined as an unintentional change in position  
60

1  
2 resulting in coming to rest on the ground or other lower level <sup>(26)</sup>. Patients were asked to  
3  
4 return their fall diaries by mail at 3 and 6 months, and during the study visit at 1, 2 and 3  
5  
6 year of follow-up. They were contacted by telephone if the fall diary was not received or  
7  
8 incomplete. Patients were categorized as those with at least one incident fall (*i.e.*, faller)  
9  
10 or without an incident fall (*i.e.*, non-faller) during follow-up.  
11  
12

13  
14 When patients recorded a fall in their diary, they were also asked to record  
15  
16 whether or not they sustained a subsequent clinical fracture as a direct result of the fall.  
17  
18 Additionally, at 1-, 2-, and 3-year follow-up, patients had to complete a detailed  
19  
20 questionnaire, including a question on whether they sustained a fracture due to another  
21  
22 trauma than a fall or without an overt trauma. All subsequent fractures were  
23  
24 radiologically confirmed according to radiology reports in the electronic patient records.  
25  
26 Since no imaging of the spine was performed at the end of the study, all reported  
27  
28 vertebral fractures were symptomatic, clinical vertebral fractures. A distinction was  
29  
30 made between subsequent fractures that were directly caused by a fall (*i.e.*, fall-related  
31  
32 fractures), and those that occurred without an overt trauma or were the result of  
33  
34 another trauma than a fall (*i.e.*, non-fall-related fractures).  
35  
36  
37  
38  
39  
40  
41

### 42 **Data analysis**

43  
44 Baseline characteristics were compared between fallers and non-fallers, and between  
45  
46 patients with and without subsequent fractures using the Student's t test or Wilcoxon  
47  
48 test for continuous variables, and Chi-squared or Fisher's exact test for categorical  
49  
50 variables where appropriate. The incidence rate of falls and subsequent fractures per  
51  
52 100 person-years was estimated at 3 and 6 months and 1, 2 and 3 year follow-up,  
53  
54 assuming a Poisson distribution. Kaplan Meier curves were made for incident falls and  
55  
56 subsequent fractures, in which patients were included once, and only the first incident  
57  
58 fall or subsequent fracture was included. Cox proportional hazards regression was used  
59  
60

1  
2 to determine the association between incident falls and subsequent fractures, yielding  
3  
4 hazard ratios (HR) and 95% confidence intervals (CI). Proportional hazard assumptions  
5  
6 were not violated. Follow-up time was determined by the first subsequent fracture, lost-  
7  
8 to-follow-up or the end of the study, whatever occurred first. All analyses were adjusted  
9  
10 for the predefined covariates, including age, gender, index fracture type (major or hip  
11  
12 versus any other fracture), BMD (lowest measured at lumbar spine, total hip, femoral  
13  
14 neck), prevalent vertebral fractures (moderate or severe versus mild or no prevalent  
15  
16 vertebral fractures). Lowest BMD was measured at the femoral neck in 470 participants,  
17  
18 at the total hip in 3 participants, and at the lumbar spine in 15 participants. A p-value <  
19  
20  
21  
22  
23 0.05 was considered statistically significant.

24  
25 Two sensitivity analyses were planned; (i) excluding patients with index and  
26  
27 subsequent finger or toe fractures, and (ii) by classifying patients with a non-fall-related  
28  
29 subsequent fracture as non-faller, even if they fell at another time during follow-up.  
30  
31  
32  
33  
34

### 35 ***Patient and public involvement***

36  
37 Patients or members of the public were not involved in the design, or conduct, or  
38  
39 reporting, or dissemination plans of the research.  
40  
41  
42  
43

## 44 **Results**

### 45 ***Study population***

46  
47 Among 1220 patients approached from the FLS, 1011 patients met the study  
48  
49 criteria. Of the 1011 patients, 511 were not willing or able to participate in the study,  
50  
51 and after excluding 12 patients with missing fall data, ultimately 488 patients were  
52  
53 available for analysis (**Supplementary Figure 1**).  
54  
55  
56

57  
58 The mean time between the index fracture and FLS visit at which patients were  
59  
60 included for this study was  $3.9 \pm 1.1$  months for patients with a hip fracture and  $3.5 \pm 1.0$

1  
2 months for patients with other fractures. Baseline characteristics of the 488 study  
3  
4 participants are presented in **Table 1**. Mean age was  $64.6 \pm 8.6$  year and 71.9% of the  
5  
6 patients were women. In 86.5% of patients, the index fracture was caused by a fall, and  
7  
8 28.5% of patients had at least one other fall in the year before the start of the study. At  
9  
10 baseline, 21.9% of patients were diagnosed with osteoporosis, 51.1% with osteopenia,  
11  
12 and 27.1% had a normal BMD. Moderate to severe (i.e., grade 2-3) prevalent vertebral  
13  
14 fractures were present in 14.3% of patients. AOM was prescribed in 34.2% of patients (8  
15  
16 (1.6%) were already using AOM, and 159 (32.6%) started using AOM at baseline visit).

17  
18  
19  
20  
21 Compared to eligible FLS attenders, who were not willing or able to participate in  
22  
23 our study, patients included in our study were younger, had fewer major or hip  
24  
25 fractures, had a higher BMD, and a lower proportion had prevalent vertebral fractures  
26  
27 (see **Supplementary Table 1**).

## 31 32 Falls

33  
34  
35 During a median follow-up of 3 years (range 0.1 to 3.0), 296 (60.7%) patients  
36  
37 recorded 959 falls, corresponding to 68.6 falls per 100 person-years. The cumulative fall  
38  
39 incidences and incidence rates per 100 person-years at 3 and 6 months, and at 1, 2 and 3  
40  
41 year follow-up are presented in **Figure 1**. Of the 296 patients with at least one fall, 115  
42  
43 (38.9%) had one fall and 181 (61.1%) had two or more falls (up to 39 falls in one  
44  
45 patient).

46  
47  
48 A first fall was recorded by 189/488 (38.7%) patients during the first year of  
49  
50 follow-up, by 56/299 (18.7%) during the second, and by 51/243 (21.0%) during the  
51  
52 third year of follow-up. The median time to the first fall was 34 (range 1-156) weeks. Of  
53  
54 the 959 falls, 47 (4.9%) resulted in a subsequent fall-related fracture.

55  
56  
57  
58 There were no significant differences in baseline characteristics between patients  
59  
60 with and without a fall during the 3-year follow-up, except for that a higher proportion

1  
2 of patients with incident falls reported at least one fall in the year before the start of the  
3  
4 study (34.5% vs. 19.3%,  $p < 0.001$ ) (see **Table 1**). There were no significant differences  
5  
6 in baseline characteristics between patients with one fall and those with multiple falls  
7  
8 (data not shown).  
9

### 10 11 12 13 ***Subsequent fractures*** 14

15  
16 In total, 53 (10.9%) patients recorded 60 subsequent fractures, corresponding to  
17  
18 4.29 subsequent fractures per 100 person-years. The cumulative subsequent fracture  
19  
20 incidences and incidence rates (per 100-person years) at 3 and 6 months, and at 1, 2 and  
21  
22 3 year follow-up are presented in **Figure 2**. Of all subsequent fractures, 47 (78.3%) were  
23  
24 fall-related, and 13 (21.7%) were non-fall-related. Fall-related subsequent fracture sites  
25  
26 were: radius and ulna (n=9), tibia and fibula (n=8), proximal femur (n=4), metatarsal  
27  
28 (n=4), hand phalanx (n=4), symptomatic vertebra (n=3), proximal humerus (n=3),  
29  
30 clavicle (n=3), costal bones (n=2), scapula (n=2), pelvic bone (n=1), metacarpal (n=1),  
31  
32 tarsal (n=1), patella (n=1), and foot phalanx (n=1), whereas subsequent non-fall-related  
33  
34 fractures sites were: symptomatic vertebral (n=5), metatarsal (n=2), foot phalanx (n=5),  
35  
36 and hand phalanx (n=1). Half (53.2%) of all fall-related subsequent fractures were  
37  
38 sustained at the first fall.  
39  
40  
41  
42  
43

44 Baseline characteristics for patients with and without subsequent fractures are  
45  
46 presented in **Table 1**.  
47

48  
49 Of the 296 patients with at least one fall, 41 (13.9%) had 46 fall-related subsequent  
50  
51 fractures, 7 (2.4%) had 7 non-fall-related subsequent fractures, and 1 (0.3%) had 1 fall-  
52  
53 and 1 non-fall-related subsequent fracture. Of the 192 patients without a fall, 4 (2.1%)  
54  
55 had 5 non-fall-related subsequent fractures. Of note, the risk of subsequent fractures was  
56  
57 higher in patients with at least one fall than in those without a fall (adjusted HR (95% CI):  
58  
59 8.6 (3.1-23.8); cumulative incidence: 16.6% versus 2.1%) (**Figure 3 and Table 2**).  
60

1  
2 Results were similar when femoral neck BMD instead of the lowest BMD was used for  
3  
4 adjustments (adjusted HR (95% CI): 8.3 (3.0-23.0)). Additionally, subsequent fracture  
5  
6 risk was higher in patients with moderate or severe prevalent vertebral fractures than in  
7  
8 those with no or mild prevalent vertebral fractures (adjusted HR (95% CI): 3.9 (2.1-7.3);  
9  
10 cumulative incidence: 24.3% versus 8.6%) (**Table 2**).

11  
12  
13 The association between falls and subsequent fractures remained significant in  
14  
15 sensitivity analyses (i) excluding patients with index and subsequent finger and toe  
16  
17 fractures (adjusted HR (95% CI): 8.2 (2.5-26.6)), and (ii) by classifying patients with a  
18  
19 non-fall-related subsequent fracture as non-faller (adjusted HR (95% CI): 2.9 (1.5-5.6)).  
20  
21  
22  
23  
24

## 25 Discussion

26  
27 In this 3-year prospective observational cohort study in patients aged 50+ years  
28  
29 with a recent clinical fracture, treated according to current Dutch osteoporosis  
30  
31 guidelines at a FLS, 60.7% of patients had at least one fall, and 10.9% had at least one  
32  
33 subsequent fracture. The majority (78.3%) of subsequent fractures was caused by a fall,  
34  
35 and of all fall-related subsequent fractures, 53.2% occurred at the first fall. Subsequent  
36  
37 fracture risk was nine-fold higher in fallers than in non-fallers.  
38  
39  
40

41  
42 Literature reporting fall incidence in fracture patients is limited. Comparable to  
43  
44 our results, Van Helden et al. <sup>(27)</sup> reported a 3-month fall incidence of 15% in patients  
45  
46 with a recent fracture at a FLS, and Matsumoto et al. <sup>(28)</sup> reported a 1-year fall incidence  
47  
48 of 40% in ambulatory patients with a recent fracture. Various other studies included  
49  
50 older, hip fracture patients and reported higher one year fall incidences up to 55% <sup>(7-11)</sup>,  
51  
52 except for the study from Yeh et al. that reported a lower 1-year fall incidence (31%) <sup>(29)</sup>.  
53  
54 Higher fall incidences in hip fracture studies can partially be explained by the older  
55  
56 study population. Unfortunately, other fall risk factors cannot be compared. An  
57  
58 explanation for the lower fall incidence in the study by Yeh et al. may be that  
59  
60

1  
2 information on the occurrence of falls was provided by patients and family caregivers,  
3  
4 which may have resulted in under registration of falls.  
5

6  
7 A comparison between the fall incidence in our study and that in the general  
8  
9 population is difficult to make, because population-based studies were conducted in a  
10  
11 65+ aged, community-dwelling population, whereas approximately 50% of our study  
12  
13 population was <65 years old. The proportion of community-dwelling people aged 65+  
14  
15 years sustaining at least one fall over a 1-year period ranged from 28 to 35%<sup>(30-32)</sup>, with  
16  
17 an increasing incidence with increasing age<sup>(33)</sup>. The 1-year fall incidence reported in our  
18  
19 study is comparable to that in an older (65+ aged) population, and therefore relatively  
20  
21 high. However, in contrast to what has been reported in literature, we found no higher  
22  
23 3-year fall incidence with increasing age. An explanation for this could be that, especially  
24  
25 in the older age group, relatively more healthy patients participated in our study,  
26  
27 resulting in a lower fall incidence in older age group. Another explanation could be that  
28  
29 patients aged 50-65 years are more physically active, and therefore fall more often.  
30  
31  
32  
33

34  
35 Compared to our results, previously published FLS studies reported lower<sup>(34,35)</sup>,  
36  
37 similar<sup>(27,36,37)</sup>, and higher<sup>(38,39)</sup> subsequent fracture rates. Differences can be explained  
38  
39 by differences in patient selection. Studies that included older patients<sup>(38)</sup> and patients  
40  
41 with more severe fractures<sup>(39)</sup> reported higher subsequent fracture rates, whereas  
42  
43 studies that excluded hand and foot index and subsequent fractures<sup>(34)</sup> or frail patients  
44  
45 reported lower rates<sup>(35)</sup>.  
46  
47  
48

49  
50 In 2010, the Dutch population consisted of approximately 6,000,000 people  
51  
52 aged 50+ years, of whom 119,419 sustained a fracture that year<sup>(40)</sup>, corresponding to a  
53  
54 calculated annual fracture incidence of 2.0% in the general Dutch 50+ population.  
55  
56 Compared to the general Dutch 50+ population, the fracture incidence was more than 2  
57  
58 times higher in our study, even in the 3rd year of follow-up. In our study, fracture  
59  
60 incidence remained high despite treatment according to the current osteoporosis



1  
2 guideline, raising the question of what more can be done to prevent subsequent  
3  
4 fractures. Even though conflicting results have been published about the effect of fall  
5  
6 prevention strategies on subsequent fracture <sup>(41)</sup>, we hypothesize that fall interventions  
7  
8 could be effective in patients at highest risk, namely those with a recent fracture at risk  
9  
10 of falling. Furthermore, according to literature, recurrent fallers have an almost fourfold  
11  
12 increased odds of sustaining a fall-related fracture compared to individuals with a single  
13  
14 fall <sup>(42)</sup>. However, we found that the majority of subsequent fall-related fractures occur at  
15  
16 the first fall after the index fracture, with a median time to the first fall of 34 weeks.  
17  
18 Moreover, fall incidence was highest in the first year. This implies that the FLS patients  
19  
20 with a high fall risk should be identified immediately, because there is a small window of  
21  
22 opportunity to prevent falls and fall-related subsequent fractures.  
23  
24  
25  
26

27  
28 Remarkably, in contrast to previous studies indicating that imminent fracture  
29  
30 risk that was highest in the first year after an index fracture <sup>(43,44)</sup>, there was a linear  
31  
32 subsequent fracture incidence during 3-year follow-up in this study. An explanation for  
33  
34 the linear subsequent fracture incidence may be the relatively healthy patients who  
35  
36 agreed to participate in our study. Compared to non-attenders, they were younger, and a  
37  
38 lower proportion had a major baseline fracture, a prevalent vertebral fracture, and  
39  
40 osteoporosis, and if indicated, were more likely to receive AOM. Importantly, in addition  
41  
42 to falls, moderate to severe prevalent vertebral fractures at baseline were associated  
43  
44 with subsequent fractures, even though anti-osteoporosis medication had been  
45  
46 prescribed to these patients according to the current Dutch osteoporosis guideline.  
47  
48  
49

50  
51 This study has several limitations. Although, this is one of the largest prospective  
52  
53 studies in a FLS population focusing on the incidence of falls after an index fracture, the  
54  
55 number of patients is modest, and the number of subsequent fractures relatively low.  
56  
57 Therefore, the association between falls and fall-related, and non-fall-related  
58  
59 subsequent fractures could not be analyzed separately. A fall 'not-resulting-in-a-  
60

1  
2 subsequent-fracture' might indicate frailty of patients, and might be different from those  
3  
4 falls that directly resulted in a subsequent fracture. Future studies are needed to  
5  
6 investigate this difference. Finally, because of small numbers, subgroup analyses should  
7  
8 not be performed. Furthermore, data on falls were collected prospectively using fall  
9  
10 diaries that had to be returned at 3 and 6 months, and 1, 2, and 3 year. However, no  
11  
12 procedures were in place to validate self-reported falls, and it is possible that recall bias,  
13  
14 could have led to under registration of falls. Moreover, no information was available on  
15  
16 falls between the index fracture and enrollment in the study. Finally, relatively healthy  
17  
18 patients participated in the study. Compared to non-attenders, they were younger, a  
19  
20 lower proportion had a major baseline fracture, a prevalent vertebral fracture, and  
21  
22 osteoporosis. The proportion of patients with a fall and subsequent fractures could be  
23  
24 expected to be even higher in the total FLS population.  
25  
26  
27  
28  
29

30  
31 In conclusion, in this 3-year prospective observational cohort study in FLS  
32  
33 patients, subsequent fracture incidence was high despite being prescribed anti-  
34  
35 osteoporosis medications according to the current Dutch osteoporosis guideline.  
36  
37 Subsequent fracture risk was nine-fold higher in fallers than in non-fallers, and the  
38  
39 majority of fall-related subsequent fractures occurred at the first fall at a median time of  
40  
41 34 weeks. These findings emphasize that immediate attention for fall risk reduction  
42  
43 could be beneficial in FLS care. Further research is needed to determine predictors for  
44  
45 falls to identify patients at highest risk of falling.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Figures and tables

**Table 1.** Baseline characteristics of 488 participants stratified by incident fall and subsequent fracture status.

	<b>Total population</b> (n=488)	<b>Non-fallers</b> (n=192)	<b>Fallers</b> (n=296)	<b>P-value</b>	<b>No subsequent fracture</b> (n=435)	<b>Subsequent fracture</b> (n=53)	<b>P-value</b>
<b>Age (years)</b>	64.6 ± 8.6	64.4 ± 8.0	64.8 ± 9.0	0.608	64.5 ± 8.8	65.3 ± 7.1	0.488
<b>Female gender</b>	351 (71.9)	130 (67.7)	221 (74.7)	0.095	308 (70.8)	43 (81.1)	0.114
<b>Baseline fracture</b>							
- Finger or toe	55 (11.3)	30 (15.6)	25 (8.4)	0.060	49 (11.3)	6 (11.3)	0.460
- Minor	303 (62.1)	109 (56.8)	194 (65.5)		270 (62.1)	33 (62.3)	
- Major	104 (21.3)	44 (22.9)	60 (20.3)		95 (21.8)	9 (17.0)	
- Hip	26 (5.3)	9 (4.7)	17 (5.7)		21 (4.8)	5 (9.4)	
- Fall-related *	422 (86.5)	164 (85.4)	258 (87.2)	0.582	378 (86.9)	44 (83.0)	0.436
<b>Fall previous year §</b>							
- 0	349 (71.5)	155 (80.7)	194 (65.5)	<0.001	315 (72.4)	34 (64.2)	0.208
- ≥ 1	139 (28.5)	37 (19.3)	102 (34.5)		120 (27.6)	19 (35.8)	
<b>BMD</b>							
- Normal BMD	132 (27.1)	54 (28.1)	78 (26.4)	0.906	123 (28.3)	9 (17.0)	0.081
- Osteopenia	249 (51.0)	97 (50.5)	152 (51.4)		222 (51.0)	27 (50.9)	
- Osteoporosis	107 (21.9)	41 (21.4)	66 (22.3)		90 (20.7)	17 (32.1)	
<b>Prevalent vertebral fracture #§</b>							
- None	356 (73.0)	139 (72.4)	217 (73.3)	0.572	328 (75.4)	28 (52.8)	<0.001
- Grade 1	62 (12.7)	22 (11.5)	40 (13.5)		54 (12.4)	8 (15.1)	
- Grade 2-3	70 (14.3)	31 (16.1)	39 (13.2)		53 (12.2)	17 (32.1)	
<b>Anti-osteoporosis treatment</b>	167 (34.2)	70 (36.5)	97 (32.8)	0.402	142 (32.6)	25 (47.2)	0.035

Continuous variables are shown in mean ± SD (standard deviation), categorical variables are shown as number of patients (%). \* Signifying that fracture was caused by a fall. § Fall resulting in baseline fracture not included. # According to Genant et al. \$ According to most severe prevalent vertebral fracture. Abbreviations: BMD, bone mineral density.

**Table 2.** Predictors of refracture: results of the Cox's proportional hazard model

Predictor	Unit of comparison	Hazard ratio and 95% confidence interval	P-value
Gender	Women vs men	1.39 (0.68 - 2.83)	0.362
Age	+5 years	0.97 (0.82 - 1.13)	0.662
Index fracture	Major or hip vs all other	0.68 (0.35 - 1.33)	0.263
BMD	-0.12 g/cm <sup>2</sup>	1.30 (0.95 - 1.78)	0.101
Prevalent vertebral fracture	Yes vs no	3.88 (2.07 - 7.27)	<0.0001
Fall	Yes vs no	8.58 (3.09 - 23.8)	<0.0001

For peer review only

1  
2  
3 **Figure legends**  
4  
5

6 **Figure 1.** Cumulative incidence of falls stratified by gender.  
7

8 **Figure 2.** Cumulative incidence of subsequent fractures stratified by gender.  
9

10 **Figure 3.** Cumulative incidence of subsequent fractures stratified by fall status.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## Contributors

LV collected data, carried out data analysis and drafted the manuscript. CW and JB developed the study design and wrote the research protocol, collected data, and critically reviewed the manuscript. PG developed the study design and wrote the research protocol, and critically reviewed the manuscript. RV collected data and critically reviewed the manuscript. TN and TT assisted with data analysis and critically reviewed the manuscript. HJ, SK, JD, JA, JC and DB critically reviewed the manuscript. All authors approved the final version of the manuscript.

## Competing interest

Dr. Vranken, Dr. Wyers, Dr. Van der Velden, Dr. Janzing, Dr. Kaarsemakers, Dr. Driessen, Dr. Eisman, Dr. Tran, and Dr. Bliuc have nothing to disclose.

Dr. Center reports honoraria for educational talks from Amgen, part support for educational meetings from Amgen, and advisory board participation for Amgen and Bayer, outside the submitted work.

Dr. Nguyen reports honoraria for lectures sponsored from Merck, and participation as executive member Asia Pacific Consortium on Osteoporosis, outside the submitted work.

Dr. Geusens reports grants from Amgen, Pfizer, MSD, UCB, Abbott, Lilly, BMS, Novartis, Roche, and Will Pharma, and honoraria for lectures from Amgen and Lilly, outside the submitted work.

Dr. van den Bergh reports grants for lectures from UCB, and Amgen, outside the submitted work.

## Funding

This work was supported by the Weijerhorst Foundation, grand number not applicable. The Weijerhorst Foundation was not involved in conducting the study, analyzing the data or writing the manuscript.

1  
2  
3  
4  
5  
6 **Patient consent for publication**  
7

8 Patient consent for publication was not required.  
9  
10  
11  
12

13 **Ethics approval**  
14

15  
16 This study (protocol ID number NL45707.072.13) has been approved by the Independent  
17  
18 Review Board Nijmegen (IRBN).  
19  
20  
21  
22

23 **Data availability statement**  
24

25  
26 No additional data available.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

1. Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, De Laet C, Jonsson B. Fracture risk following an osteoporotic fracture. *Osteoporos Int*. 2003 Dec 23;15(3):175–9.
2. Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, Eisman J, Fujiwara S, Garnero P, Kroger H, McCloskey EV, Mellstrom D, Melton LJ, Pols H, Reeve J, Silman A, Tenenhouse A. A meta-analysis of previous fracture and subsequent fracture risk. *Bone*. 2004 Aug;35(2):375–82.
3. van Helden S, Cals J, Kessels F, Brink P, Dinant G-J, Geusens P. Risk of new clinical fractures within 2 years following a fracture. *Osteoporosis International*. 2006;17(3):348–54.
4. Center JR, Bliuc D, Nguyen TV, Eisman JA. Risk of Subsequent Fracture After Low-Trauma Fracture in Men and Women. *JAMA*. American Medical Association; 2007 Jan 24;297(4):387–94.
5. Briggs AM, Sun W, Miller LJ, Geelhoed E, Huska A, Inderjeeth CA. Hospitalisations, admission costs and re-fracture risk related to osteoporosis in Western Australia are substantial: a 10-year review. *Aust N Z J Public Health*. 2015 Dec;39(6):557–62.
6. Balasubramanian A, Zhang J, Chen L, Wenkert D, Daigle SG, Grauer A, Curtis JR. Risk of subsequent fracture after prior fracture among older women. *Osteoporos Int*. 2019 Jan;30(1):79–92.
7. McKee KJ, Orbell S, Austin CA, Bettridge R, Liddle BJ, Morgan K, Radley K. Fear of falling, falls efficacy, and health outcomes in older people following hip fracture. *Disabil Rehabil*. 2002 Apr 15;24(6):327–33.



- 1  
2  
3 8. Shumway-Cook A, Ciol MA, Gruber W, Robinson C. Incidence of and risk factors for  
4 falls following hip fracture in community-dwelling older adults. *Phys Ther.* 2005  
5  
6 Jul;85(7):648–55.  
7
- 8  
9  
10 9. Kristensen MT, Foss NB, Kehlet H. Timed “up & go” test as a predictor of falls  
11  
12 within 6 months after hip fracture surgery. *Phys Ther.* 2007 Jan;87(1):24–30.  
13
- 14  
15 10. Berggren M, Stenvall M, Olofsson B, Gustafson Y. Evaluation of a fall-prevention  
16  
17 program in older people after femoral neck fracture: a one-year follow-up.  
18  
19 *Osteoporosis International.* 2008 Jun;19(6):801–9.  
20
- 21  
22 11. Lloyd BD, Williamson DA, Singh NA, Hansen RD, Diamond TH, Finnegan TP, Allen  
23  
24 BJ, Grady JN, Stavrinou TM, Smith EUR, Diwan AD, Fiatarone Singh MA. Recurrent  
25  
26 and injurious falls in the year following hip fracture: a prospective study of  
27  
28 incidence and risk factors from the Sarcopenia and Hip Fracture study. *J. Gerontol.*  
29  
30 *A Biol. Sci. Med. Sci.* 2009 May;64(5):599–609.  
31
- 32  
33 12. Masud T, Morris RO. Epidemiology of falls. *Age and Ageing.* 2001 Nov;30 Suppl  
34  
35 4(suppl 4):3–7.  
36
- 37  
38 13. Morrison A, Fan T, Sen SS, Weisenfluh L. Epidemiology of falls and osteoporotic  
39  
40 fractures: a systematic review. *Clinicoecon Outcomes Res.* Dove Press; 2013;5:9–  
41  
42 18.  
43
- 44  
45 14. Geusens P, Autier P, Boonen S, Vanhoof J, Declerck K, Raus J. The relationship  
46  
47 among history of falls, osteoporosis, and fractures in postmenopausal women.  
48  
49 *Arch Phys Med Rehabil.* 2002 Jul;83(7):903–6.  
50
- 51  
52 15. Kaptoge S, Benevolenskaya LI, Bhalla AK, Cannata JB, Boonen S, Falch JA,  
53  
54 Felsenberg D, Finn JD, Nuti R, Hozowski K, Lorenc R, Miazgowski T, Jajic I, Lyritis  
55  
56 G, Masaryk P, Naves-Diaz M, Poor G, Reid DM, Scheidt-Nave C, Stepan JJ, Todd CJ,  
57  
58 Weber K, Woolf AD, Roy DK, Lunt M, Pye SR, O'Neill TW, Silman AJ, Reeve J. Low  
59  
60

- 1  
2  
3 BMD is less predictive than reported falls for future limb fractures in women  
4  
5 across Europe: results from the European Prospective Osteoporosis Study. *Bone*.  
6  
7 2005 Mar;36(3):387–98.  
8  
9
- 10  
11 16. Harvey NC, Odén A, Orwoll E, Lapidus J, Kwok T, Karlsson MK, Rosengren BE,  
12  
13 Ljunggren O, Cooper C, McCloskey E, Kanis JA, Ohlsson C, Mellström D, Johansson  
14  
15 H. Falls Predict Fractures Independently of FRAX Probability: A Meta-Analysis of  
16  
17 the Osteoporotic Fractures in Men (MrOS) Study. *Journal of Bone and Mineral*  
18  
19 *Research*. John Wiley & Sons, Ltd; 2017 Dec 8;33(3):510–6.  
20  
21
- 22 17. Leslie WD, Morin SN, Lix LM, Martineau P, Bryanton M, McCloskey EV, Johansson  
23  
24 H, Harvey NC, Kanis JA. Fracture prediction from self-reported falls in routine  
25  
26 clinical practice: a registry-based cohort study. *Osteoporos Int*. Springer London;  
27  
28 2019 Nov;30(11):2195–203.  
29  
30
- 31 18. Eisman JA, Bogoch ER, Dell R, Harrington JT, McKinney RE Jr., McLellan A, Mitchell  
32  
33 PJ, Silverman S, Singleton R, Siris E, for the ASBMR Task Force on Secondary  
34  
35 Fracture Prevention. Making the first fracture the last fracture: ASBMR task force  
36  
37 report on secondary fracture prevention. *Journal of Bone and Mineral Research*.  
38  
39 Wiley Subscription Services, Inc., A Wiley Company; 2012 Jul 26;27(10):2039–46.  
40  
41
- 42 19. Lems WF, Dreinhöfer KE, Bischoff-Ferrari H, Blauth M, Czerwinski E, da Silva J,  
43  
44 Herrera A, Hoffmeyer P, Kvien T, Maalouf G, Marsh D, Puget J, Puhl W, Poor G,  
45  
46 Rasch L, Roux C, Schüler S, Seriola B, Tarantino U, van Geel T, Woolf A, Wyers C,  
47  
48 Geusens P. EULAR/EFORT recommendations for management of patients older  
49  
50 than 50 years with a fragility fracture and prevention of subsequent fractures. *Ann*  
51  
52 *Rheum Dis*. 2016 Dec 22;:annrheumdis-2016-210289-10.  
53  
54  
55
- 56 20. IOF Fracture Working Group, Åkesson K, Marsh D, Mitchell PJ, McLellan AR,  
57  
58 Stenmark J, Pierroz DD, Kyer C, Cooper C. Capture the Fracture: a Best Practice  
59  
60

- 1  
2  
3 Framework and global campaign to break the fragility fracture cycle. *Osteoporos*  
4  
5 *Int.* Springer London; 2013 Apr 16;24(8):2135–52.  
6  
7  
8 21. Dreinhöfer KE, Mitchell PJ, Bégué T, Cooper C, Costa ML, Falaschi P, Hertz K, Marsh  
9  
10 D, Maggi S, Nana A, Palm H, Speerin R, Magaziner J, on behalf of: the Fragility  
11  
12 Fracture Network (FFN), European Geriatric Medicine Society (EuGMS), European  
13  
14 Federation of National Associations of Orthopaedics and Traumatology (EFORT),  
15  
16 International Collaboration of Orthopaedic Nursing (ICON), International Geriatric  
17  
18 Fracture Society (IGFS), International Osteoporosis Foundation (IOF). A global call  
19  
20 to action to improve the care of people with fragility fractures. *Injury*. 2018  
21  
22 Aug;49(8):1393–7.  
23  
24  
25  
26 22. Javaid MK, Sami A, Lems W, Mitchell P, Thomas T, Singer A, Speerin R, Fujita M,  
27  
28 Pierroz DD, Åkesson K, Halbout P, Ferrari S, Cooper C. A patient-level key  
29  
30 performance indicator set to measure the effectiveness of fracture liaison services  
31  
32 and guide quality improvement: a position paper of the IOF Capture the Fracture  
33  
34 Working Group, National Osteoporosis Foundation and Fragility Fracture Network.  
35  
36 *Osteoporos Int.* 2020 Apr 8;4(5):e001806.  
37  
38  
39  
40 23. Bours SPG, van Geel TACM, Geusens PPMM, Janssen MJW, Janzing HMJ, Hoffland  
41  
42 GA, Willems PC, van den Bergh JPW. Contributors to secondary osteoporosis and  
43  
44 metabolic bone diseases in patients presenting with a clinical fracture. *The Journal*  
45  
46 *of Clinical Endocrinology & Metabolism*. 2011 May;96(5):1360–7.  
47  
48  
49  
50 24. Werkgroep CBO, Richtlijn Osteoporose en Fractuurpreventie, derde herziening  
51  
52 [Dutch]. (CBO, Utrecht, 2011).  
53  
54  
55 25. Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a  
56  
57 semiquantitative technique. *Journal of Bone and Mineral Research*. John Wiley and  
58  
59  
60

- 1  
2  
3 Sons and The American Society for Bone and Mineral Research (ASBMR); 1993  
4  
5 Sep;8(9):1137–48.  
6  
7  
8 26. The prevention of falls in later life. A report of the Kellogg International Work  
9  
10 Group on the Prevention of Falls by the Elderly. *Dan Med Bull.* 1987 Apr;34 Suppl  
11  
12 4:1–24.  
13  
14  
15 27. van Helden S, Wyers CE, Dagnelie PC, van Dongen MC, Willems G, Brink PR,  
16  
17 Geusens PP. Risk of falling in patients with a recent fracture. *BMC Musculoskeletal*  
18  
19 *Disorders.* BioMed Central; 2007 Jun 28;8(1):348.  
20  
21  
22 28. Matsumoto H, Makabe T, Morita T, Ikuhara K, Kajigase A, Okamoto Y, Ashikawa E,  
23  
24 Kobayashi E, Hagino H. Accelerometry-based gait analysis predicts falls among  
25  
26 patients with a recent fracture who are ambulatory: a 1-year prospective study. *Int*  
27  
28 *J Rehabil Res.* 2015 Jun;38(2):131–6.  
29  
30  
31 29. Yeh H-F, Shao J-H, Li C-L, Wu C-C, Shyu Y-IL. Predictors of postoperative falls in the  
32  
33 first and second postoperative years among older hip fracture patients. *J Clin Nurs.*  
34  
35 3rd ed. 2017 Nov;26(21-22):3710–23.  
36  
37  
38 30. Prudham D, Evans JG. Factors associated with falls in the elderly: a community  
39  
40 study. *Age and Ageing.* 1981 Aug;10(3):141–6.  
41  
42  
43 31. Campbell AJ, Reinken J, Allan BC, Martinez GS. Falls in old age: a study of frequency  
44  
45 and related clinical factors. *Age and Ageing.* 1981 Nov;10(4):264–70.  
46  
47  
48 32. Blake AJ, Morgan K, Bendall MJ, Dallosso H, Ebrahim SB, Arie TH, Fentem PH,  
49  
50 Bassey EJ. Falls by elderly people at home: prevalence and associated factors. *Age*  
51  
52 *and Ageing.* 1988 Nov;17(6):365–72.  
53  
54  
55 33. World Health Organization WHO. WHO Global Report on Falls Prevention in Older  
56  
57 Age. 2017 Jan 6;:1–53.  
58  
59  
60

- 1  
2  
3 34. Eekman DA, van Helden SH, Huisman AM, Verhaar HJJ, Bultink IEM, Geusens PP,  
4 Lips P, Lems WF. Optimizing fracture prevention: the fracture liaison service, an  
5 observational study. *Osteoporos Int*. Springer London; 2013 Sep 13;25(2):701–9.  
6  
7  
8  
9  
10 35. Lih A, Nandapalan H, Kim M, Yap C, Lee P, Ganda K, Seibel MJ. Targeted  
11 intervention reduces refracture rates in patients with incident non-vertebral  
12 osteoporotic fractures: a 4-year prospective controlled study. *Osteoporos Int*.  
13 Springer-Verlag; 2011 Mar;22(3):849–58.  
14  
15  
16  
17  
18  
19 36. Van der Kallen J, Giles M, Cooper K, Gill K, Parker V, Tembo A, Major G, Ross L,  
20 Carter J. A fracture prevention service reduces further fractures two years after  
21 incident minimal trauma fracture. *Int J Rheum Dis*. John Wiley & Sons, Ltd  
22 (10.1111); 2014 Feb;17(2):195–203.  
23  
24  
25  
26  
27  
28  
29 37. Huntjens KM, van Geel TA, van Helden S, van den Bergh J, Willems P, Winkens B,  
30 Geusens PP, Brink PR. The role of the combination of bone and fall related risk  
31 factors on short-term subsequent fracture risk and mortality. *BMC Musculoskeletal*  
32 *Disorders*. BioMed Central; 2013 Apr 4;14(1):721.  
33  
34  
35  
36  
37  
38 38. Sanli I, van Helden SH, Broeke Ten RHM, Geusens P, van den Bergh JPW, Brink PRG,  
39 Poeze M. The role of the Fracture Liaison Service (FLS) in subsequent fracture  
40 prevention in the extreme elderly. *Aging Clin Exp Res*. 2018 Oct 11;31(8):1105–11.  
41  
42  
43  
44  
45 39. Deloumeau A, Moltó A, Roux C, Briot K. Determinants of short term fracture risk in  
46 patients with a recent history of low-trauma non-vertebral fracture. *Bone*. 2017  
47 Dec;105:287–91.  
48  
49  
50  
51  
52 40. Lötters FJB, van den Bergh JP, de Vries F, Rutten-van Mölken MPMH. Current and  
53 Future Incidence and Costs of Osteoporosis-Related Fractures in The Netherlands:  
54 Combining Claims Data with BMD Measurements. *Calcified Tissue International*.  
55 Springer US; 2016 Mar;98(3):235–43.  
56  
57  
58  
59  
60

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
41. Wang Q, Jiang X, Shen Y, Yao P, Chen J, Zhou Y, Gu Y, Qian Z, Cao X. Effectiveness of exercise intervention on fall-related fractures in older adults: a systematic review and meta-analysis of randomized controlled trials. *BMC Geriatr. BioMed Central*; 2020 Sep 4;20(1):322–11.
  42. Pluijm SMF, Smit JH, Tromp EAM, Stel VS, Deeg DJH, Bouter LM, Lips P. A risk profile for identifying community-dwelling elderly with a high risk of recurrent falling: results of a 3-year prospective study. *Osteoporosis International*. 2006;17(3):417–25.
  43. van Geel TACM, Huntjens KMB, van den Bergh JPW, Dinant G-J, Geusens PP. Timing of Subsequent Fractures after an Initial Fracture. *Curr Osteoporos Rep*. 2010 Jun 18;8(3):118–22.
  44. van Geel TACM, van Helden S, Geusens PP, Winkens B, Dinant G-J. Clinical subsequent fractures cluster in time after first fractures. *Ann Rheum Dis*. 2008 Jul 29;68(1):99–102.





Figure 1. Cumulative incidence of falls stratified by gender.



	0	13	26	52	104	156
Men (N (%))	0	3 (2.2)	3 (2.2)	4 (2.9)	6 (4.4)	10 (7.3)
Women (N (%))	0	4 (1.1)	8 (2.3)	18 (5.1)	27 (7.7)	43 (12.3)
Total (per 100 person years)	-	5.8	4.6	4.8	3.9	4.3

**Figure 2.** Cumulative incidence of subsequent fractures stratified by gender.







Figure 3. Cumulative incidence of subsequent fractures stratified by fall status.

## Supplementary tables and figures



**Supplementary Figure 1.** Patient selection. Abbreviations: HET, high-energy trauma fractures; Fx, fracture.

**Supplementary table 1.** Characteristics of 1011 FLS patients that participated and not-participated in this study.

	<b>Participants</b> (n=500)	<b>Non-participants</b> (n=511)	<b>P-value</b>
Age in years	64.6 ± 8.6	68.3 ± 9.8	<.001
Female sex	357 (71.4)	396 (77.5)	.026
Baseline fracture			
- Finger or toe	58 (11.6)	53 (10.4)	<.001
- Minor	311 (62.2)	259 (50.7)	
- Major	105 (21.0)	157 (30.7)	
- Hip	26 (5.2)	42 (8.2)	
- Fall-related *	431 (86.2)	441 (86.3)	.963
Fall previous year §			
- 0	356 (71.2)	359 (70.3)	.741
- ≥ 1	144 (28.8)	152 (29.7)	
- ≥ 2	72 (14.4)	87 (17.0)	.252
BMD			
- Normal BMD	135 (27.0)	90 (17.6)	<.001
- Osteopenia	255 (51.0)	258 (50.5)	
- Osteoporosis	110 (22.0)	163 (31.9)	
Prevalent vertebral fracture			
- None	366 (73.2)	349 (68.3)	.010
- Grade 1	63 (12.6)	53 (10.4)	
- Grade 2-3	71 (14.2)	109 (21.3)	
At least one fall past year	143 (29.3)	152 (29.9)	.704

Continues variables are presented as mean ± SD, categorical variables are presented as number of patients (%). § Fall resulting in baseline fracture not included. # According to Genant et al. § According to most severe prevalent vertebral fracture. Abbreviations: BMD, bone mineral density

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page No
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1,3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3,4
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	5,6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5,6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	5,6
		(b) For matched studies, give matching criteria and number of exposed and unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6,7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6,7
Bias	9	Describe any efforts to address potential sources of bias	8
Study size	10	Explain how the study size was arrived at	5,6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7,8
		(b) Describe any methods used to examine subgroups and interactions	8
		(c) Explain how missing data were addressed	8
		(d) If applicable, explain how loss to follow-up was addressed	8
		(e) Describe any sensitivity analyses	8
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8
		(b) Give reasons for non-participation at each stage	8
		(c) Consider use of a flow diagram	20
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	15
		(b) Indicate number of participants with missing data for each variable of interest	NA
		(c) Summarise follow-up time (eg, average and total amount)	9
Outcome data	15*	Report numbers of outcome events or summary measures over time	9,10,16,17,18

1	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9,10,11
2			(b) Report category boundaries when continuous variables were categorized	NA
3			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	9,10
4				
5				
6				
7				
8				
9	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	11
10				
11	<b>Discussion</b>			
12				
13	Key results	18	Summarise key results with reference to study objectives	11
14	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	13
15				
16	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12,13,14
17				
18				
19	Generalisability	21	Discuss the generalisability (external validity) of the study results	14
20				
21	<b>Other information</b>			
22	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	1
23				
24				
25				

26 \*Give information separately for exposed and unexposed groups.

27  
28 **Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and  
29 published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely  
30 available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at  
31 <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is  
32 available at <http://www.strobe-statement.org>.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# BMJ Open

## Incident falls are strongly associated with subsequent fracture risk in patients attending the Fracture Liaison Service after an index fracture: a 3-year prospective cohort study.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-058983.R1
Article Type:	Original research
Date Submitted by the Author:	18-Apr-2022
Complete List of Authors:	Vranken, Lisanne; VieCuri Medical Centre, Department of Internal Medicine; Maastricht University Medical Centre+, Department of Internal Medicine, Research School NUTRIM Wyers, Caroline; VieCuri Medical Centre, Department of Internal Medicine; Maastricht University Medical Centre+, Department of Internal Medicine, Research School NUTRIM Van der Velde, R.Y.; VieCuri Medical Centre, Department of Internal Medicine; Maastricht University Medical Centre+, Department of Internal Medicine, Research School NUTRIM Janzing, Heinrich M. J.; VieCuri Medical Centre, Department of Surgery Kaarsemakers, S.; VieCuri Medical Centre, Department of Orthopedic Surgery Driessen, Johanna; Maastricht University Medical Centre+, Department of Clinical Pharmacy and Toxicology; Maastricht University, Department of Clinical Pharmacy and Toxicology Eisman, John; Garvan Institute of Medical Research, Osteoporosis and bone biology; The University of Notre Dame Australia, School of Medicine Sydney Center, Jacqueline; Garvan Institute of Medical Research, Osteoporosis and bone biology; UNSW, School of Population Health Nguyen, T.V.; Garvan Institute of Medical Research; UNSW, School of Population, Faculty of Medicine Tran, Thach; Garvan Institute of Medical Research, Bone Biology Division Bliuc, Dana; Garvan Institute of Medical Research, Bone and Mineral Research Program Geusens, Piet; Maastricht Universitair Medisch Centrum+, Department of Internal Medicine, Subdivision Reumatology; Maastricht University, CAPHRI School for Public Health and Primary Care van den Bergh, Joop; Maastricht Universitair Medisch Centrum+, Department of Internal Medicine, Research School NUTRIM; VieCuri Medisch Centrum, Department of Internal Medicine
<b>Primary Subject Heading</b>:	Epidemiology
Secondary Subject Heading:	Rheumatology, Geriatric medicine, General practice / Family practice
Keywords:	INTERNAL MEDICINE, Orthopaedic & trauma surgery < SURGERY,

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

	GENERAL MEDICINE (see Internal Medicine)

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.



1  
2  
3 **Incident falls are strongly associated with subsequent fracture risk in patients**  
4 **attending the Fracture Liaison Service after an index fracture: a 3-year**  
5 **prospective cohort study.**  
6  
7  
8  
9

10  
11  
12 L. Vranken <sup>1,2,3</sup>, C.E. Wyers <sup>1,2,3</sup>, R.Y. Van der Velde <sup>1,2,3</sup>, H.M.J. Janzing <sup>4</sup>, S. Kaarsemakers <sup>5</sup>,  
13  
14 J.H.M. Driessen <sup>6,7</sup>, J.A. Eisman <sup>8,9,10</sup>, J.R. Center <sup>8,10</sup>, T.V. Nguyen <sup>8,10,11</sup>, T. Tran <sup>8</sup>, D. Bliuc <sup>8</sup>,  
15  
16 P.P.M.M. Geusens <sup>12,13,14</sup>, J.P. Van den Bergh <sup>1,2,3,14,\*</sup>  
17  
18  
19  
20  
21

- 22 1. Department of Internal Medicine, VieCuri Medical Center, Venlo, The Netherlands  
23  
24 2. Department of Internal Medicine, Maastricht University Medical Center +,  
25  
26 Maastricht, The Netherlands  
27  
28 3. NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht  
29  
30 University, Maastricht, The Netherlands  
31  
32 4. Department of Surgery, VieCuri Medical Center, Venlo, The Netherlands  
33  
34 5. Department of Orthopedic Surgery, VieCuri Medical Center, Venlo, The Netherlands  
35  
36 6. Department of Clinical Pharmacy and Toxicology, NUTRIM School of Nutrition and  
37  
38 Translational Research in Metabolism, CARIM School for Cardiovascular Disease,  
39  
40 Maastricht University Medical Center +, P.O. Box 5800, 6202 AZ Maastricht, The  
41  
42 Netherlands  
43  
44 7. Department of Clinical Pharmacy and Toxicology, CAPHRI School for Public Health  
45  
46 and Primary Care, Maastricht University, Maastricht, The Netherlands  
47  
48 8. Osteoporosis and Bone Biology, Garvan Institute of Medical Research, Sydney,  
49  
50 Australia  
51  
52 9. School of Medicine Sydney, University of Notre Dame Australia, Sydney, Australia  
53  
54  
55  
56  
57 10. School of Population Health, Faculty of Medicine, UNSW Sydney, Sydney, Australia  
58  
59  
60

- 1  
2  
3 11. School of Biomedical Engineering, University of Technology Sydney, Sydney,  
4  
5 Australia  
6  
7  
8 12. CAPHRI School for Public Health and Primary Care, Maastricht University,  
9  
10 Maastricht, The Netherlands  
11  
12 13. Department of Internal Medicine, Subdivision Rheumatology, Maastricht University  
13  
14 Medical Center +, Maastricht, The Netherlands  
15  
16  
17 14. Faculty of Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium  
18  
19 \* Corresponding author  
20  
21  
22  
23  
24  
25

### Corresponding author

26 Name: J.P. van den Bergh

27  
28 Postal address: Tegelseweg 210, 5912 BL Venlo

29  
30 E-mail: j@vdbergh.org

31  
32 Telephone: 0031-773205555

33  
34 Fax numbers: 0031-773206279  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Abstract****Objectives:**

Falls are a strong risk factor for fractures, independent of bone mineral density (BMD) and clinical risk factors. The aim of this study was to evaluate the risk of subsequent fractures in patients who attended the Fracture Liaison Service (FLS), with and without incident falls after the index fracture.

**Method:**

A 3-year prospective observational cohort study was conducted in patients aged 50+ years with a recent clinical fracture, starting at the time they attended the FLS. Patients were treated with anti-osteoporosis medication according to the Dutch osteoporosis guideline. Falls were recorded weekly in fall diaries. Subsequent fractures were recorded in fall diaries and annual questionnaires and were radiologically confirmed. The Cox's proportional hazards model was employed to estimate the association between fall and fracture risk, adjusted for predefined covariates including age, gender, index fracture type, BMD, and prevalent vertebral fractures status.

**Results:**

The study included 488 patients (71.9% women, mean age  $64.6 \pm 8.6$  years). During the 3-year follow-up, 959 falls had been ascertained in 296 (60.7%) patients (*i.e.*, fallers), and 60 subsequent fractures were ascertained in 53 (10.9%) patients. Of the fractures, 47 (78.3%) were fall-related, of which 25 (53.2%) were sustained at the first fall incident at a median of 34 weeks. An incident fall was associated with an approximately 9-fold (hazard ratio 8.6; 95% CI, 3.1 to 23.8) increase in the risk of subsequent fractures.

**Conclusion:**

These data suggest that subsequent fractures among patients on treatment prescribed in a FLS setting are common, and an incident falls is a strong predictor of subsequent

1  
2  
3 fracture risk, and that immediate attention for fall risk could be beneficial in an FLS  
4  
5 model of care.  
6  
7  
8  
9

### 10 **Strengths and limitations**

- 12 - Although this is one of the largest prospective studies in a FLS population  
13 focusing on the incidence of falls after an index fracture, the number of patients is  
14 modest, and the number of subsequent fractures relatively small.  
15  
16  
17  
18
- 19 - Data on falls were collected prospectively using fall diaries. However, no  
20 procedures were in place to validate self-reported falls.  
21  
22  
23
- 24 - No information was available on falls between the index fracture and enrollment  
25 in the study.  
26  
27  
28
- 29 - Relatively healthy patients participated in the study, which may have resulted in  
30 an underestimation of incident falls and subsequent fractures.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 1 Introduction

2 Patients with a recent fracture have a high imminent risk of subsequent fractures  
3 as shown after most fractures (1-6), and a high risk of subsequent falls, as shown after a  
4 recent hip fracture (7-11). The Fracture Liaison Service (FLS) is considered the most  
5 effective organizational approach for secondary fracture prevention in patients after the  
6 age of 50 years with a recent fracture.

7 Most fractures are caused by a fall, but most falls do not result in a fracture  
8 (12,13). Falls are a major contributing factor to the occurrence of fractures, independent  
9 and additive to the risk attributable to age and bone mineral density (BMD) (14-17).  
10 Guidelines on the FLS therefore recommend fall prevention and prescription of anti-  
11 osteoporosis medication (AOM) in high risk patients (18-22). However, it is not well  
12 known to what extent the imminent risk of subsequent fractures after an index fracture  
13 can be attributed to incident falls. We hypothesized that the risk of subsequent fractures  
14 would be substantially higher in patients with falls after a recent fracture than in those  
15 without falls. The aim of this study was therefore to evaluate the incidence of falls and  
16 subsequent fractures, and the risk of subsequent fractures in those with and without  
17 falls after a recent index fracture in patients who attend the FLS.

## 18 Methods

### 19 *Study population and design*

20 A 3-year prospective observational cohort study was conducted including 500  
21 consecutive patients aged between 50 and 90 years with a recent, radiologically  
22 confirmed clinical vertebral or non-vertebral low-trauma fracture, and who were willing  
23 and able to participate. Patients were recruited at the FLS in VieCuri Medical Center,  
24 Venlo, The Netherlands.

1  
2 26 Low-trauma fractures were defined as fractures that resulted from a fall from standing  
3  
4 27 height or less. Excluded were non-Caucasian patients, patients with bone metastasis,  
5  
6 28 failure of prosthesis or osteomyelitis, and patients with cognitive impairment.  
7  
8

9 29 According to standard care, a nurse specialized in osteoporosis invited all  
10  
11 30 patients aged 50 year and older, who visited the emergency department because of a  
12  
13 31 recent clinical vertebral or non-vertebral fracture, to the FLS. All patients who  
14  
15 32 responded and agreed to be evaluated were scheduled an appointment for fracture risk  
16  
17 33 evaluation. Fracture risk evaluation included a detailed questionnaire for evaluation of  
18  
19 34 risk factors for fractures and falls, including medical history and medication use. This  
20  
21 35 questionnaire was based on the Dutch guidelines on osteoporosis and fracture prevention, and  
22  
23 36 prevention of falls in the elderly (23,24). Also, height and weight were measured, a bone  
24  
25 37 mineral density (BMD) measurement with dual-energy X-ray absorptiometry (DXA) of  
26  
27 38 the lumbar spine, total hip, and femoral neck, with vertebral fracture assessment (VFA)  
28  
29 39 was performed, and a blood sample was collected to detect contributors to secondary  
30  
31 40 osteoporosis and metabolic bone disease (25). According to the Dutch osteoporosis  
32  
33 41 guideline (23), AOM was started in patients with osteoporosis or having at least one  
34  
35 42 moderate to severe prevalent vertebral fracture according to Genant et al. (26).  
36  
37 43 Bisphosphonates and denosumab were first-choice treatments. Teriparatide was  
38  
39 44 restricted to patients already on another AOM with at least 3 fractures, of which 2 were  
40  
41 45 vertebral fractures.  
42  
43  
44  
45  
46  
47

48 46 The study protocol (registration number NL45707.072.13) was approved by an  
49  
50 47 independent Medical Ethics Committee and complied with the Declaration of Helsinki.  
51  
52 48 All patients gave written informed consent prior to participation.  
53  
54  
55  
56  
57

## 58 49 ***Falls and subsequent fractures***

59  
60

1  
2 51 During the 3-year follow-up, patients were requested to record falls weekly in a  
3  
4 52 fall diary. Fall registration started at the beginning of the study, mean  $3.5 \pm 1.0$  months  
5  
6 53 after the index fracture. A fall was defined as an unintentional change in position  
7  
8  
9 54 resulting in coming to rest on the ground or other lower level (27). Patients were asked  
10  
11 55 to return their fall diaries by mail at 3 and 6 months, and during the study visit at 1, 2  
12  
13 56 and 3 year of follow-up. They were contacted by telephone if the fall diary was not  
14  
15  
16 57 received or incomplete. Patients were categorized as those with at least one incident fall  
17  
18 58 (*i.e.*, faller) or without an incident fall (*i.e.*, non-faller) during follow-up.  
19

20  
21 59 When patients recorded a fall in their diary, they were also asked to record  
22  
23 60 whether or not they sustained a subsequent clinical fracture as a direct result of the fall.  
24  
25 61 Additionally, at 1-, 2-, and 3-year follow-up, patients had to complete a detailed  
26  
27 62 questionnaire, including a question on whether they sustained a fracture due to another  
28  
29 63 trauma than a fall or without an overt trauma. All subsequent fractures were  
30  
31 64 radiologically confirmed according to radiology reports in the electronic patient records.  
32  
33 65 Since no imaging of the spine was performed at the end of the study, all reported  
34  
35 66 vertebral fractures were symptomatic, clinical vertebral fractures. A distinction was  
36  
37 67 made between subsequent fractures that were directly caused by a fall (*i.e.*, fall-related  
38  
39 68 fractures), and those that occurred without an overt trauma or were the result of  
40  
41 69 another trauma than a fall (*i.e.*, non-fall-related fractures).  
42  
43  
44  
45  
46  
47  
48

## 49 71 **Data analysis**

50  
51 72 Baseline characteristics were compared between fallers and non-fallers, and between  
52  
53 73 patients with and without subsequent fractures using the Student's t test or Wilcoxon  
54  
55 74 test for continuous variables, and Chi-squared or Fisher's exact test for categorical  
56  
57 75 variables where appropriate. The incidence rate of falls and subsequent fractures per  
58  
59 76 100 person-years was estimated at 3 and 6 months and 1, 2 and 3 year follow-up,  
60

1  
2 77 assuming a Poisson distribution. Kaplan Meier curves were made for incident falls and  
3  
4 78 subsequent fractures, in which patients were included once, and only the first incident  
5  
6 79 fall or subsequent fracture was included. Cox proportional hazards regression was used  
7  
8  
9 80 to determine the association between incident falls and subsequent fractures, yielding  
10  
11 81 hazard ratios (HR) and 95% confidence intervals (CI). Proportional hazard assumptions  
12  
13 82 were not violated. Follow-up time was determined by the first subsequent fracture, lost-  
14  
15 83 to-follow-up or the end of the study, whatever occurred first. All analyses were adjusted  
16  
17 84 for the predefined covariates, including age, gender, index fracture type (major or hip  
18  
19 85 versus any other fracture), BMD (lowest measured at lumbar spine, total hip, femoral  
20  
21 86 neck), prevalent vertebral fractures (moderate or severe versus mild or no prevalent  
22  
23 87 vertebral fractures). A p-value < 0.05 was considered statistically significant.

24  
25  
26  
27 88 Two sensitivity analyses were planned; (i) excluding patients with index and  
28  
29 89 subsequent finger or toe fractures, and (ii) by classifying patients with a non-fall-related  
30  
31 90 subsequent fracture as non-faller, even if they fell at another time during follow-up.  
32  
33  
34

35 91

### 36 37 92 ***Patient and public involvement***

38  
39 93 Patients or members of the public were not involved in the design, or conduct, or  
40  
41 94 reporting, or dissemination plans of the research.  
42  
43

44 95

## 45 46 96 **Results**

### 47 48 97 ***Study population***

49  
50 98 Among 1220 patients approached from the FLS, 1011 patients met the study  
51  
52 99 criteria. Of the 1011 patients, 511 were not willing or able to participate in the study,  
53  
54 100 and after excluding 12 patients with missing fall data, ultimately 488 patients were  
55  
56 101 available for analysis (**Supplementary Figure 1**) of whom 34 (7.0%) patients had  
57  
58  
59  
60



1  
2 102 incomplete follow-up data on incident falls (5 patients died, 8 withdrew consent, 21 had  
3  
4 103 incomplete fall registration).  
5

6 104 The mean time between the index fracture and FLS visit at which patients were  
7  
8  
9 105 included for this study was  $3.9 \pm 1.1$  months for patients with a hip fracture and  $3.5 \pm 1.0$   
10  
11 106 months for patients with other fractures. Baseline characteristics of the 488 study  
12  
13 107 participants are presented in **Table 1**. Mean age was  $64.6 \pm 8.6$  year and 71.9% of the  
14  
15 108 patients were women. In 86.5% of patients, the index fracture was caused by a fall, and  
16  
17 109 28.5% of patients had at least one other fall in the year before the start of the study. At  
18  
19 110 baseline, 21.9% of patients were diagnosed with osteoporosis, 51.1% with osteopenia,  
20  
21 111 and 27.1% had a normal BMD. Lowest BMD was measured at the femoral neck in 470  
22  
23 112 participants, at the total hip in 3 participants, and at the lumber spine in 15 participants.  
24  
25 113 Moderate to severe (i.e., grade 2-3) prevalent vertebral fractures were present in 14.3%  
26  
27 114 of patients. AOM was prescribed in 34.2% of patients (8 (1.6%) were already using AOM,  
28  
29 115 and 159 (32.6%) started using AOM at baseline visit).  
30  
31  
32  
33

34 116 Compared to eligible FLS attenders, who were not willing or able to participate in  
35  
36 117 our study, patients included in our study were younger, had fewer major or hip  
37  
38 118 fractures, had a higher BMD, and a lower proportion had prevalent vertebral fractures  
39  
40 119 (see **Supplementary Table 1**).  
41  
42  
43

44 120

## 46 121 Falls

48 122 During a median follow-up of 3 years (range 0.1 to 3.0), 296 (60.7%) patients  
49  
50 123 recorded 959 falls, corresponding to 68.6 falls per 100 person-years. The cumulative fall  
51  
52 124 incidences and incidence rates per 100 person-years at 3 and 6 months, and at 1, 2 and 3  
53  
54 125 year follow-up are presented in **Figure 1**. Of the 296 patients with at least one fall, 115  
55  
56 126 (38.9%) had one fall and 181 (61.1%) had two or more falls (up to 39 falls in one  
57  
58 127 patient).  
59  
60

1  
2 128 A first fall was recorded by 189/488 (38.7%) patients during the first year of  
3  
4 129 follow-up, by 56/299 (18.7%) during the second, and by 51/243 (21.0%) during the  
5  
6 130 third year of follow-up. The median time to the first fall was 34 (range 1-156) weeks. Of  
7  
8  
9 131 the 959 falls, 47 (4.9%) resulted in a subsequent fall-related fracture.

10  
11 132 There were no significant differences in baseline characteristics between patients  
12  
13 133 with and without a fall during the 3-year follow-up, except for that a higher proportion  
14  
15 134 of patients with incident falls reported at least one fall in the year before the start of the  
16  
17 135 study (34.5% vs. 19.3%,  $p < 0.001$ ) (see **Table 1**). There were no significant differences  
18  
19 136 in baseline characteristics between patients with one fall and those with multiple falls  
20  
21 137 (data not shown).  
22  
23  
24  
25  
26  
27

### 28 139 ***Subsequent fractures***

29  
30 140 In total, 53 (10.9%) patients recorded 60 subsequent fractures, corresponding to  
31  
32 141 4.29 subsequent fractures per 100 person-years. The cumulative subsequent fracture  
33  
34 142 incidences and incidence rates (per 100-person years) at 3 and 6 months, and at 1, 2 and  
35  
36 143 3 year follow-up are presented in **Figure 2**. Of all subsequent fractures, 47 (78.3%) were  
37  
38 144 fall-related, and 13 (21.7%) were non-fall-related. Fall-related subsequent fracture sites  
39  
40 145 were: radius and ulna (n=9), tibia and fibula (n=8), proximal femur (n=4), metatarsal  
41  
42 146 (n=4), hand phalanx (n=4), symptomatic vertebra (n=3), proximal humerus (n=3),  
43  
44 147 clavicle (n=3), costal bones (n=2), scapula (n=2), pelvic bone (n=1), metacarpal (n=1),  
45  
46 148 tarsal (n=1), patella (n=1), and foot phalanx (n=1), whereas subsequent non-fall-related  
47  
48 149 fractures sites were: symptomatic vertebral (n=5), metatarsal (n=2), foot phalanx (n=5),  
49  
50 150 and hand phalanx (n=1). Half (53.2%) of all fall-related subsequent fractures were  
51  
52 151 sustained at the first fall.  
53  
54  
55  
56  
57

58 152 Baseline characteristics for patients with and without subsequent fractures are  
59  
60 153 presented in **Table 1**.

1  
2 154 Of the 296 patients with at least one fall, 41 (13.9%) had 46 fall-related subsequent  
3  
4 155 fractures, 7 (2.4%) had 7 non-fall-related subsequent fractures, and 1 (0.3%) had 1 fall-  
5  
6 156 and 1 non-fall-related subsequent fracture. Of the 192 patients without a fall, 4 (2.1%)  
7  
8  
9 157 had 5 non-fall-related subsequent fractures. Of note, the risk of subsequent fractures was  
10  
11 158 higher in patients with at least one fall than in those without a fall (adjusted HR (95% CI):  
12  
13 159 8.6 (3.1-23.8); cumulative incidence: 16.6% versus 2.1%) (**Figure 3 and Table 2**).  
14  
15  
16 160 Results were similar when femoral neck BMD instead of the lowest BMD was used for  
17  
18 161 adjustments (adjusted HR (95% CI): 8.3 (3.0-23.0)). Additionally, subsequent fracture  
19  
20 162 risk was higher in patients with moderate or severe prevalent vertebral fractures than in  
21  
22  
23 163 those with no or mild prevalent vertebral fractures (adjusted HR (95% CI): 3.9 (2.1-7.3);  
24  
25 164 cumulative incidence: 24.3% versus 8.6%) (**Table 2**).

26  
27  
28 165 The association between falls and subsequent fractures remained significant in  
29  
30 166 sensitivity analyses (i) excluding patients with index and subsequent finger and toe  
31  
32 167 fractures (adjusted HR (95% CI): 8.2 (2.5-26.6)), and (ii) by classifying patients with a  
33  
34 168 non-fall-related subsequent fracture as non-faller (adjusted HR (95% CI): 2.9 (1.5-5.6)).  
35  
36

37 169

## 39 170 **Discussion**

40  
41  
42 171 In this 3-year prospective observational cohort study in patients aged 50+ years  
43  
44 172 with a recent clinical fracture, treated according to current Dutch osteoporosis  
45  
46 173 guidelines at a FLS, 60.7% of patients had at least one fall, and 10.9% had at least one  
47  
48 174 subsequent fracture. The majority (78.3%) of subsequent fractures was caused by a fall,  
49  
50 175 and of all fall-related subsequent fractures, 53.2% occurred at the first fall. Subsequent  
51  
52 176 fracture risk was nine-fold higher in fallers than in non-fallers.

53  
54  
55  
56 177 Literature reporting fall incidence in fracture patients is limited. Comparable to  
57  
58 178 our results, Van Helden et al. (28) reported a 3-month fall incidence of 15% in patients  
59  
60 179 with a recent fracture at a FLS, and Matsumoto et al. (29) reported a 1-year fall

1  
2 180 incidence of 40% in ambulatory patients with a recent fracture. Various other studies  
3  
4 181 included older, hip fracture patients and reported higher one year fall incidences up to  
5  
6 182 55% (7-11), except for the study from Yeh et al. that reported a lower 1-year fall  
7  
8  
9 183 incidence (31%) (30). Higher fall incidences in hip fracture studies can partially be  
10  
11 184 explained by the older study population. Unfortunately, other fall risk factors cannot be  
12  
13  
14 185 compared. An explanation for the lower fall incidence in the study by Yeh et al. may be  
15  
16 186 that information on the occurrence of falls was provided by patients and family  
17  
18 187 caregivers, which may have resulted in under registration of falls.  
19

20  
21 188 A comparison between the fall incidence in our study and that in the general  
22  
23 189 population is difficult to make, because population-based studies were conducted in a  
24  
25 190 65+ aged, community-dwelling population, whereas approximately 50% of our study  
26  
27 191 population was <65 years old. The proportion of community-dwelling people aged 65+  
28  
29 192 years sustaining at least one fall over a 1-year period ranged from 28 to 35% (31-33),  
30  
31 193 with an increasing incidence with increasing age (34). The 1-year fall incidence reported  
32  
33 194 is our study is comparable to that in an older (65+ aged) population, and therefore  
34  
35 195 relatively high. However, in contrast to what has been reported in literature, we found  
36  
37 196 no higher 3-year fall incidence with increasing age. An explanation for this could be that,  
38  
39 197 especially in the older age group, relatively more healthy patients participated in our  
40  
41 198 study, resulting in a lower fall incidence in older age group. Another explanation could  
42  
43 199 be that patients aged 50-65 years are more physically active, and therefore fall more  
44  
45 200 often.  
46  
47  
48  
49

50  
51 201 Compared to our results, previously published FLS studies reported lower <sup>(34,35)</sup>,  
52  
53 202 similar (28,37,38), and higher (39,40) subsequent fracture rates. Differences can be  
54  
55 203 explained by differences in patient selection. Studies that included older patients (39)  
56  
57 204 and patients with more severe fractures (40) reported higher subsequent fracture rates,  
58  
59  
60

1  
2 205 whereas studies that excluded hand and foot index and subsequent fractures (35) or  
3  
4 206 frail patients reported lower rates (36).  
5  
6 207 In 2010, the Dutch population consisted of approximately 6,000,000 people aged 50+  
7  
8 208 years, of whom 119,419 sustained a fracture that year (41), corresponding to a  
9  
10 209 calculated annual fracture incidence of 2.0% in the general Dutch 50+ population.  
11  
12 210 Compared to the general Dutch 50+ population, the fracture incidence was more than 2  
13  
14 211 times higher in our study, even in the 3rd year of follow-up. In our study, fracture  
15  
16 212 incidence remained high despite treatment according to the current osteoporosis  
17  
18 213 guideline, raising the question of what more can be done to prevent subsequent  
19  
20 214 fractures. Even though conflicting results have been published about the effect of fall  
21  
22 215 prevention strategies on subsequent fracture (42), we hypothesize that fall  
23  
24 216 interventions could be effective in patients at highest risk, namely those with a recent  
25  
26 217 fracture at risk of falling. Furthermore, according to literature, recurrent fallers have an  
27  
28 218 almost fourfold increased odds of sustaining a fall-related fracture compared to  
29  
30 219 individuals with a single fall (43). However, we found that the majority of subsequent  
31  
32 220 fall-related fractures occur at the first fall after the index fracture, with a median time to  
33  
34 221 the first fall of 34 weeks. Interestingly, fall incidence was higher in the first year of  
35  
36 222 follow-up compared to the second and third year. This may indicate an imminent fall  
37  
38 223 risk, which may attribute to the imminent subsequent fracture risk after an index  
39  
40 224 fracture (1-6). This implies that the FLS patients with a high fall risk should be identified  
41  
42 225 immediately, because there is a small window of opportunity to prevent falls and fall-  
43  
44 226 related subsequent fractures.  
45  
46  
47  
48  
49  
50  
51  
52

53 227 Remarkably, in contrast to previous studies indicating that imminent fracture  
54  
55 228 risk that was highest in the first year after an index fracture (44,45), there was a linear  
56  
57 229 subsequent fracture incidence during 3-year follow-up in this study. An explanation for  
58  
59 230 the linear subsequent fracture incidence may be the relatively healthy patients who  
60

1  
2 231 agreed to participate in our study. Compared to non-attenders, they were younger, and a  
3  
4 232 lower proportion had a major baseline fracture, a prevalent vertebral fracture, and  
5  
6 233 osteoporosis, and if indicated, were more likely to receive AOM. Importantly, in addition  
7  
8 234 to falls, moderate to severe prevalent vertebral fractures at baseline were associated  
9  
10 235 with subsequent fractures, even though anti-osteoporosis medication had been  
11  
12 236 prescribed to these patients according to the current Dutch osteoporosis guideline.  
13  
14  
15

16 237       This study has several limitations. Although, this is one of the largest prospective  
17  
18 238 studies in a FLS population focusing on the incidence of falls after an index fracture, the  
19  
20 239 number of patients is modest, and the number of subsequent fractures relatively low.  
21  
22  
23 240 Therefore, the association between falls and fall-related, and non-fall-related  
24  
25 241 subsequent fractures could not be analyzed separately. A fall 'not-resulting-in-a-  
26  
27 242 subsequent-fracture' might indicate frailty of patients, and might be different from those  
28  
29 243 falls that directly resulted in a subsequent fracture. Future studies are needed to  
30  
31 244 investigate this difference. Finally, because of small numbers, subgroup analyses should  
32  
33 245 not be performed. Furthermore, data on falls were collected prospectively using fall  
34  
35 246 diaries that had to be returned at 3 and 6 months, and 1, 2, and 3 year. However, no  
36  
37 247 procedures were in place to validate self-reported falls, and it is possible that recall bias,  
38  
39 248 could have led to underregistration of falls. Moreover, no information was available on  
40  
41 249 falls between the index fracture and enrollment in the study. Finally, relatively healthy  
42  
43 250 patients participated in the study. Compared to non-attenders, they were younger, a  
44  
45 251 lower proportion had a major baseline fracture, a prevalent vertebral fracture, and  
46  
47 252 osteoporosis. The proportion of patients with a fall and subsequent fractures could be  
48  
49 253 expected to be even higher in the total FLS population.  
50  
51  
52  
53  
54

55 254       In conclusion, in this 3-year prospective observational cohort study in FLS  
56  
57 255 patients, subsequent fracture incidence was high despite being prescribed anti-  
58  
59 256 osteoporosis medications according to the current Dutch osteoporosis guideline.  
60

1  
2 257 Subsequent fracture risk was nine-fold higher in fallers than in non-fallers, and the  
3  
4 258 majority of fall-related subsequent fractures occurred at the first fall at a median time of  
5  
6 259 34 weeks. These findings emphasize that immediate attention for fall risk reduction  
7  
8 260 could be beneficial in FLS care. Various risk factors, including comorbidities, medication  
9  
10 261 use, polypharmacy and alcohol use among others, contribute to patient's fall risk and  
11  
12 262 further research is needed to determine predictors for falls to identify patients at  
13  
14 263 highest risk of falling.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Figures and tables

**Table 1.** Baseline characteristics of 488 participants stratified by incident fall and subsequent fracture status.

	<b>Total population</b> (n=488)	<b>Non-fallers</b> (n=192)	<b>Fallers</b> (n=296)	<b>P-value</b>	<b>No subsequent fracture</b> (n=435)	<b>Subsequent fracture</b> (n=53)	<b>P-value</b>
<b>Age (years)</b>	64.6 ± 8.6	64.4 ± 8.0	64.8 ± 9.0	0.608	64.5 ± 8.8	65.3 ± 7.1	0.488
<b>Female gender</b>	351 (71.9)	130 (67.7)	221 (74.7)	0.095	308 (70.8)	43 (81.1)	0.114
<b>Baseline fracture</b>							
- Finger or toe	55 (11.3)	30 (15.6)	25 (8.4)	0.060	49 (11.3)	6 (11.3)	0.460
- Minor	303 (62.1)	109 (56.8)	194 (65.5)		270 (62.1)	33 (62.3)	
- Major	104 (21.3)	44 (22.9)	60 (20.3)		95 (21.8)	9 (17.0)	
- Hip	26 (5.3)	9 (4.7)	17 (5.7)		21 (4.8)	5 (9.4)	
- Fall-related *	422 (86.5)	164 (85.4)	258 (87.2)	0.582	378 (86.9)	44 (83.0)	0.436
<b>Fall previous year §</b>							
- 0	349 (71.5)	155 (80.7)	194 (65.5)	<0.001	315 (72.4)	34 (64.2)	0.208
- ≥ 1	139 (28.5)	37 (19.3)	102 (34.5)		120 (27.6)	19 (35.8)	
<b>BMI (kg/m<sup>2</sup>)</b>	27.7 ± 4.4	27.7 ± 4.4	27.7 ± 4.4	0.961	27.8 ± 4.4	26.9 ± 4.8	0.154
<b>BMD</b>							
- Normal BMD	132 (27.1)	54 (28.1)	78 (26.4)	0.906	123 (28.3)	9 (17.0)	0.081
- Osteopenia	249 (51.0)	97 (50.5)	152 (51.4)		222 (51.0)	27 (50.9)	
- Osteoporosis	107 (21.9)	41 (21.4)	66 (22.3)		90 (20.7)	17 (32.1)	
<b>Prevalent vertebral fracture #§</b>							
- None	356 (73.0)	139 (72.4)	217 (73.3)	0.572	328 (75.4)	28 (52.8)	<0.001
- Grade 1	62 (12.7)	22 (11.5)	40 (13.5)		54 (12.4)	8 (15.1)	
- Grade 2-3	70 (14.3)	31 (16.1)	39 (13.2)		53 (12.2)	17 (32.1)	
<b>Anti-osteoporosis treatment</b>	167 (34.2)	70 (36.5)	97 (32.8)	0.402	142 (32.6)	25 (47.2)	0.035

Continuous variables are shown in mean ± SD (standard deviation), categorical variables are shown as number of patients (%). \* Signifying that fracture was caused by a fall. § Fall resulting in baseline fracture not included. # According to Genant et al. \$ According to most severe prevalent vertebral fracture. Abbreviations: BMD, bone mineral density.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

<b>Predictor</b>	<b>Unit of comparison</b>	<b>Hazard ratio and 95% confidence interval</b>	<b>P-value</b>
Gender	Women vs men	1.39 (0.68 - 2.83)	0.362
Age	+5 years	0.97 (0.82 - 1.13)	0.662
Index fracture	Major or hip vs all other	0.68 (0.35 - 1.33)	0.263
BMD	-0.12 g/cm <sup>2</sup>	1.30 (0.95 - 1.78)	0.101
Prevalent vertebral fracture	Yes vs no	3.88 (2.07 - 7.27)	<0.0001
Fall	Yes vs no	8.58 (3.09 - 23.8)	<0.0001

1  
2  
3 **Figure legends**  
4  
5

6 **Figure 1.** Cumulative incidence of falls stratified by gender.  
7

8 **Figure 2.** Cumulative incidence of subsequent fractures stratified by gender.  
9

10 **Figure 3.** Cumulative incidence of subsequent fractures stratified by fall status.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## Contributors

LV collected data, carried out data analysis and drafted the manuscript. CW and JB developed the study design and wrote the research protocol, collected data, and critically reviewed the manuscript. PG developed the study design and wrote the research protocol, and critically reviewed the manuscript. RV collected data and critically reviewed the manuscript. TN and TT assisted with data analysis and critically reviewed the manuscript. HJ, SK, JD, JA, JC and DB critically reviewed the manuscript. All authors approved the final version of the manuscript.

## Competing interest

Dr. Vranken, Dr. Wyers, Dr. Van der Velden, Dr. Janzing, Dr. Kaarsemakers, Dr. Driessen, Dr. Eisman, Dr. Tran, and Dr. Bliuc have nothing to disclose.

Dr. Center reports honoraria for educational talks from Amgen, part support for educational meetings from Amgen, and advisory board participation for Amgen and Bayer, outside the submitted work.

Dr. Nguyen reports honoraria for lectures sponsored from Merck, and participation as executive member Asia Pacific Consortium on Osteoporosis, outside the submitted work.

Dr. Geusens reports grants from Amgen, Pfizer, MSD, UCB, Abbott, Lilly, BMS, Novartis, Roche, and Will Pharma, and honoraria for lectures from Amgen and Lilly, outside the submitted work.

Dr. van den Bergh reports grants for lectures from UCB, and Amgen, outside the submitted work.

## Funding

This work was supported by the Weijerhorst Foundation, grand number not applicable. The Weijerhorst Foundation was not involved in conducting the study, analyzing the data or writing the manuscript.

1  
2  
3  
4  
5  
6 **Patient consent for publication**  
7

8 Patient consent for publication was not required.  
9  
10

11  
12  
13 **Ethics approval**  
14

15  
16 This study (protocol ID number NL45707.072.13) has been approved by the Independent  
17  
18 Review Board Nijmegen (IRBN).  
19  
20

21  
22  
23 **Data availability statement**  
24

25  
26 No additional data available.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

1. Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, De Laet C, Jonsson B. Fracture risk following an osteoporotic fracture. *Osteoporos Int*. 2003 Dec 23;15(3):175–9.
2. Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, Eisman J, Fujiwara S, Garnero P, Kroger H, McCloskey EV, Mellstrom D, Melton LJ, Pols H, Reeve J, Silman A, Tenenhouse A. A meta-analysis of previous fracture and subsequent fracture risk. *Bone*. 2004 Aug;35(2):375–82.
3. van Helden S, Cals J, Kessels F, Brink P, Dinant G-J, Geusens P. Risk of new clinical fractures within 2 years following a fracture. *Osteoporosis International*. 2006;17(3):348–54.
4. Center JR, Bliuc D, Nguyen TV, Eisman JA. Risk of Subsequent Fracture After Low-Trauma Fracture in Men and Women. *JAMA*. American Medical Association; 2007 Jan 24;297(4):387–94.
5. Briggs AM, Sun W, Miller LJ, Geelhoed E, Huska A, Inderjeeth CA. Hospitalisations, admission costs and re-fracture risk related to osteoporosis in Western Australia are substantial: a 10-year review. *Aust N Z J Public Health*. 2015 Dec;39(6):557–62.
6. Balasubramanian A, Zhang J, Chen L, Wenkert D, Daigle SG, Grauer A, Curtis JR. Risk of subsequent fracture after prior fracture among older women. *Osteoporos Int*. 2019 Jan;30(1):79–92.
7. McKee KJ, Orbell S, Austin CA, Bettridge R, Liddle BJ, Morgan K, Radley K. Fear of falling, falls efficacy, and health outcomes in older people following hip fracture. *Disabil Rehabil*. 2002 Apr 15;24(6):327–33.

- 1  
2  
3 8. Shumway-Cook A, Ciol MA, Gruber W, Robinson C. Incidence of and risk factors for  
4 falls following hip fracture in community-dwelling older adults. *Phys Ther.* 2005  
5 Jul;85(7):648–55.  
6  
7
- 8  
9  
10 9. Kristensen MT, Foss NB, Kehlet H. Timed “up & go” test as a predictor of falls  
11 within 6 months after hip fracture surgery. *Phys Ther.* 2007 Jan;87(1):24–30.  
12  
13
- 14 10. Berggren M, Stenvall M, Olofsson B, Gustafson Y. Evaluation of a fall-prevention  
15 program in older people after femoral neck fracture: a one-year follow-up.  
16 *Osteoporosis International.* 2008 Jun;19(6):801–9.  
17  
18
- 19 11. Lloyd BD, Williamson DA, Singh NA, Hansen RD, Diamond TH, Finnegan TP, Allen  
20 BJ, Grady JN, Stavrinou TM, Smith EUR, Diwan AD, Fiatarone Singh MA. Recurrent  
21 and injurious falls in the year following hip fracture: a prospective study of  
22 incidence and risk factors from the Sarcopenia and Hip Fracture study. *J. Gerontol.*  
23 *A Biol. Sci. Med. Sci.* 2009 May;64(5):599–609.  
24  
25
- 26 12. Masud T, Morris RO. Epidemiology of falls. *Age and Ageing.* 2001 Nov;30 Suppl  
27 4(suppl 4):3–7.  
28  
29
- 30 13. Morrison A, Fan T, Sen SS, Weisenfluh L. Epidemiology of falls and osteoporotic  
31 fractures: a systematic review. *Clinicoecon Outcomes Res.* Dove Press; 2013;5:9–  
32 18.  
33  
34
- 35 14. Geusens P, Autier P, Boonen S, Vanhoof J, Declerck K, Raus J. The relationship  
36 among history of falls, osteoporosis, and fractures in postmenopausal women.  
37 *Arch Phys Med Rehabil.* 2002 Jul;83(7):903–6.  
38  
39
- 40 15. Kaptoge S, Benevolenskaya LI, Bhalla AK, Cannata JB, Boonen S, Falch JA,  
41 Felsenberg D, Finn JD, Nuti R, Hoszowski K, Lorenc R, Miazgowski T, Jajic I, Lyritis  
42 G, Masaryk P, Naves-Diaz M, Poor G, Reid DM, Scheidt-Nave C, Stepan JJ, Todd CJ,  
43 Weber K, Woolf AD, Roy DK, Lunt M, Pye SR, O'Neill TW, Silman AJ, Reeve J. Low  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 BMD is less predictive than reported falls for future limb fractures in women  
4  
5 across Europe: results from the European Prospective Osteoporosis Study. *Bone*.  
6  
7 2005 Mar;36(3):387–98.  
8  
9
- 10  
11 16. Harvey NC, Odén A, Orwoll E, Lapidus J, Kwok T, Karlsson MK, Rosengren BE,  
12  
13 Ljunggren O, Cooper C, McCloskey E, Kanis JA, Ohlsson C, Mellström D, Johansson  
14  
15 H. Falls Predict Fractures Independently of FRAX Probability: A Meta-Analysis of  
16  
17 the Osteoporotic Fractures in Men (MrOS) Study. *Journal of Bone and Mineral*  
18  
19 *Research*. John Wiley & Sons, Ltd; 2017 Dec 8;33(3):510–6.  
20  
21
- 22  
23 17. Leslie WD, Morin SN, Lix LM, Martineau P, Bryanton M, McCloskey EV, Johansson  
24  
25 H, Harvey NC, Kanis JA. Fracture prediction from self-reported falls in routine  
26  
27 clinical practice: a registry-based cohort study. *Osteoporos Int*. Springer London;  
28  
29 2019 Nov;30(11):2195–203.  
30
- 31  
32 18. Eisman JA, Bogoch ER, Dell R, Harrington JT, McKinney RE Jr., McLellan A, Mitchell  
33  
34 PJ, Silverman S, Singleton R, Siris E, for the ASBMR Task Force on Secondary  
35  
36 Fracture Prevention. Making the first fracture the last fracture: ASBMR task force  
37  
38 report on secondary fracture prevention. *Journal of Bone and Mineral Research*.  
39  
40 Wiley Subscription Services, Inc., A Wiley Company; 2012 Jul 26;27(10):2039–46.  
41  
42
- 43  
44 19. Lems WF, Dreinhöfer KE, Bischoff-Ferrari H, Blauth M, Czerwinski E, da Silva J,  
45  
46 Herrera A, Hoffmeyer P, Kvien T, Maalouf G, Marsh D, Puget J, Puhl W, Poor G,  
47  
48 Rasch L, Roux C, Schüle S, Seriola B, Tarantino U, van Geel T, Woolf A, Wyers C,  
49  
50 Geusens P. EULAR/EFORT recommendations for management of patients older  
51  
52 than 50 years with a fragility fracture and prevention of subsequent fractures. *Ann*  
53  
54 *Rheum Dis*. 2016 Dec 22;:annrheumdis-2016-210289-10.  
55  
56
- 57  
58 20. IOF Fracture Working Group, Åkesson K, Marsh D, Mitchell PJ, McLellan AR,  
59  
60 Stenmark J, Pierroz DD, Kyer C, Cooper C. Capture the Fracture: a Best Practice

- 1  
2  
3 Framework and global campaign to break the fragility fracture cycle. *Osteoporos*  
4 *Int.* Springer London; 2013 Apr 16;24(8):2135–52.  
5  
6  
7  
8 21. Dreinhöfer KE, Mitchell PJ, Bégué T, Cooper C, Costa ML, Falaschi P, Hertz K, Marsh  
9 D, Maggi S, Nana A, Palm H, Speerin R, Magaziner J, on behalf of: the Fragility  
10 Fracture Network (FFN), European Geriatric Medicine Society (EuGMS), European  
11 Federation of National Associations of Orthopaedics and Traumatology (EFORT),  
12 International Collaboration of Orthopaedic Nursing (ICON), International Geriatric  
13 Fracture Society (IGFS), International Osteoporosis Foundation (IOF). A global call  
14 to action to improve the care of people with fragility fractures. *Injury*. 2018  
15 Aug;49(8):1393–7.  
16  
17  
18 22. Javaid MK, Sami A, Lems W, Mitchell P, Thomas T, Singer A, Speerin R, Fujita M,  
19 Pierroz DD, Åkesson K, Halbout P, Ferrari S, Cooper C. A patient-level key  
20 performance indicator set to measure the effectiveness of fracture liaison services  
21 and guide quality improvement: a position paper of the IOF Capture the Fracture  
22 Working Group, National Osteoporosis Foundation and Fragility Fracture Network.  
23 *Osteoporos Int.* 2020 Apr 8;4(5):e001806.  
24  
25  
26 23. Werkgroep CBO, Richtlijn Osteoporose en Fractuurpreventie, derde herziening  
27 [Dutch]. (CBO, Utrecht, 2011).  
28  
29  
30 24. Richtlijn Preventie van valincidenten bij ouderen (2017) [Dutch].  
31 ([https://richtlijndatabase.nl/richtlijn/preventie\\_van\\_valincidenten\\_bij\\_ouderen](https://richtlijndatabase.nl/richtlijn/preventie_van_valincidenten_bij_ouderen/startpagina_-_preventie_van_valincidenten.html)  
32 [/startpagina\\_-\\_preventie\\_van\\_valincidenten.html](https://richtlijndatabase.nl/richtlijn/preventie_van_valincidenten_bij_ouderen/startpagina_-_preventie_van_valincidenten.html)).  
33  
34  
35  
36 25. Bours SPG, van Geel TACM, Geusens PPMM, Janssen MJW, Janzing HMJ, Hoffland  
37 GA, Willems PC, van den Bergh JPW. Contributors to secondary osteoporosis and  
38 metabolic bone diseases in patients presenting with a clinical fracture. *The Journal*  
39 *of Clinical Endocrinology & Metabolism*. 2011 May;96(5):1360–7.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



- 1  
2  
3 26. Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a  
4 semiquantitative technique. *Journal of Bone and Mineral Research*. John Wiley and  
5 Sons and The American Society for Bone and Mineral Research (ASBMR); 1993  
6 Sep;8(9):1137-48.  
7
- 8  
9  
10  
11  
12 27. The prevention of falls in later life. A report of the Kellogg International Work  
13 Group on the Prevention of Falls by the Elderly. *Dan Med Bull*. 1987 Apr;34 Suppl  
14 4:1-24.  
15
- 16  
17  
18  
19 28. van Helden S, Wyers CE, Dagnelie PC, van Dongen MC, Willems G, Brink PR,  
20 Geusens PP. Risk of falling in patients with a recent fracture. *BMC Musculoskeletal*  
21 *Disorders*. BioMed Central; 2007 Jun 28;8(1):348.  
22
- 23  
24  
25  
26  
27 29. Matsumoto H, Makabe T, Morita T, Ikuhara K, Kajigase A, Okamoto Y, Ashikawa E,  
28 Kobayashi E, Hagino H. Accelerometry-based gait analysis predicts falls among  
29 patients with a recent fracture who are ambulatory: a 1-year prospective study. *Int*  
30 *J Rehabil Res*. 2015 Jun;38(2):131-6.  
31
- 32  
33  
34  
35  
36 30. Yeh H-F, Shao J-H, Li C-L, Wu C-C, Shyu Y-IL. Predictors of postoperative falls in the  
37 first and second postoperative years among older hip fracture patients. *J Clin Nurs*.  
38 3rd ed. 2017 Nov;26(21-22):3710-23.  
39
- 40  
41  
42  
43 31. Prudham D, Evans JG. Factors associated with falls in the elderly: a community  
44 study. *Age and Ageing*. 1981 Aug;10(3):141-6.  
45
- 46  
47  
48 32. Campbell AJ, Reinken J, Allan BC, Martinez GS. Falls in old age: a study of frequency  
49 and related clinical factors. *Age and Ageing*. 1981 Nov;10(4):264-70.  
50
- 51  
52  
53 33. Blake AJ, Morgan K, Bendall MJ, Dallosso H, Ebrahim SB, Arie TH, Fentem PH,  
54 Bassey EJ. Falls by elderly people at home: prevalence and associated factors. *Age*  
55 *and Ageing*. 1988 Nov;17(6):365-72.  
56  
57  
58  
59  
60

- 1  
2  
3 34. World Health Organization WHO. WHO Global Report on Falls Prevention in Older  
4 Age. 2017 Jan 6;;1–53.
- 5  
6  
7  
8 35. Eekman DA, van Helden SH, Huisman AM, Verhaar HJJ, Bultink IEM, Geusens PP,  
9 Lips P, Lems WF. Optimizing fracture prevention: the fracture liaison service, an  
10 observational study. *Osteoporos Int*. Springer London; 2013 Sep 13;25(2):701–9.
- 11  
12  
13  
14  
15 36. Lih A, Nandapalan H, Kim M, Yap C, Lee P, Ganda K, Seibel MJ. Targeted  
16 intervention reduces refracture rates in patients with incident non-vertebral  
17 osteoporotic fractures: a 4-year prospective controlled study. *Osteoporos Int*.  
18 Springer-Verlag; 2011 Mar;22(3):849–58.
- 19  
20  
21  
22  
23  
24 37. Van der Kallen J, Giles M, Cooper K, Gill K, Parker V, Tembo A, Major G, Ross L,  
25 Carter J. A fracture prevention service reduces further fractures two years after  
26 incident minimal trauma fracture. *Int J Rheum Dis*. John Wiley & Sons, Ltd  
27 (10.1111); 2014 Feb;17(2):195–203.
- 28  
29  
30  
31  
32  
33 38. Huntjens KM, van Geel TA, van Helden S, van den Bergh J, Willems P, Winkens B,  
34 Geusens PP, Brink PR. The role of the combination of bone and fall related risk  
35 factors on short-term subsequent fracture risk and mortality. *BMC Musculoskeletal*  
36 *Disorders*. BioMed Central; 2013 Apr 4;14(1):721.
- 37  
38  
39  
40  
41  
42 39. Sanli I, van Helden SH, Broeke Ten RHM, Geusens P, van den Bergh JPW, Brink PRG,  
43 Poeze M. The role of the Fracture Liaison Service (FLS) in subsequent fracture  
44 prevention in the extreme elderly. *Aging Clin Exp Res*. 2018 Oct 11;31(8):1105–11.
- 45  
46  
47  
48  
49  
50 40. Deloumeau A, Moltó A, Roux C, Briot K. Determinants of short term fracture risk in  
51 patients with a recent history of low-trauma non-vertebral fracture. *Bone*. 2017  
52 Dec;105:287–91.
- 53  
54  
55  
56  
57 41. Lötters FJB, van den Bergh JP, de Vries F, Rutten-van Mölken MPMH. Current and  
58 Future Incidence and Costs of Osteoporosis-Related Fractures in The Netherlands:  
59  
60

- 1  
2  
3 Combining Claims Data with BMD Measurements. *Calcified Tissue International*.  
4  
5 Springer US; 2016 Mar;98(3):235–43.  
6  
7
- 8 42. Wang Q, Jiang X, Shen Y, Yao P, Chen J, Zhou Y, Gu Y, Qian Z, Cao X. Effectiveness of  
9  
10 exercise intervention on fall-related fractures in older adults: a systematic review  
11  
12 and meta-analysis of randomized controlled trials. *BMC Geriatr. BioMed Central*;  
13  
14 2020 Sep 4;20(1):322–11.  
15  
16
- 17 43. Pluijm SMF, Smit JH, Tromp EAM, Stel VS, Deeg DJH, Bouter LM, Lips P. A risk  
18  
19 profile for identifying community-dwelling elderly with a high risk of recurrent  
20  
21 falling: results of a 3-year prospective study. *Osteoporosis International*.  
22  
23 2006;17(3):417–25.  
24  
25
- 26 44. van Geel TACM, Huntjens KMB, van den Bergh JPW, Dinant G-J, Geusens PP. Timing  
27  
28 of Subsequent Fractures after an Initial Fracture. *Curr Osteoporos Rep*. 2010 Jun  
29  
30 18;8(3):118–22.  
31  
32
- 33 45. van Geel TACM, van Helden S, Geusens PP, Winkens B, Dinant G-J. Clinical  
34  
35 subsequent fractures cluster in time after first fractures. *Ann Rheum Dis*. 2008 Jul  
36  
37 29;68(1):99–102.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60





Figure 1. Cumulative incidence of falls stratified by gender.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



	0	13	26	52	104	156
Men (N (%))	0	3 (2.2)	3 (2.2)	4 (2.9)	6 (4.4)	10 (7.3)
Women (N (%))	0	4 (1.1)	8 (2.3)	18 (5.1)	27 (7.7)	43 (12.3)
Total (per 100 person years)	-	5.8	4.6	4.8	3.9	4.3

Figure 2. Cumulative incidence of subsequent fractures stratified by gender.





Figure 3. Cumulative incidence of subsequent fractures stratified by fall status.



**Supplementary Figure 1.** Patient selection. Abbreviations: HET, high-energy trauma fractures; Fx, fracture.

**Supplementary table 1.** Characteristics of 1011 FLS patients that participated and not-participated in this study.

	Participants (n=500)	Non-participants (n=511)	P-value
Age in years	64.6 ± 8.6	68.3 ± 9.8	<.001
Female sex	357 (71.4)	396 (77.5)	.026
Baseline fracture			
- Finger or toe	58 (11.6)	53 (10.4)	<.001
- Minor	311 (62.2)	259 (50.7)	
- Major	105 (21.0)	157 (30.7)	
- Hip	26 (5.2)	42 (8.2)	
- Fall-related *	431 (86.2)	441 (86.3)	.963
Fall previous year §			
- 0	356 (71.2)	359 (70.3)	.741
- ≥ 1	144 (28.8)	152 (29.7)	
- ≥ 2	72 (14.4)	87 (17.0)	.252
BMD			
- Normal BMD	135 (27.0)	90 (17.6)	<.001
- Osteopenia	255 (51.0)	258 (50.5)	
- Osteoporosis	110 (22.0)	163 (31.9)	
Prevalent vertebral fracture			
- None	366 (73.2)	349 (68.3)	.010
- Grade 1	63 (12.6)	53 (10.4)	
- Grade 2-3	71 (14.2)	109 (21.3)	
At least one fall past year	143 (29.3)	152 (29.9)	.704

Continues variables are presented as mean ± SD, categorical variables are presented as number of patients (%). § Fall resulting in baseline fracture not included. # According to Genant et al. § According to most severe prevalent vertebral fracture. Abbreviations: BMD, bone mineral density



STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page No
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1,3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3,4
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	5,6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5,6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	5,6
		(b) For matched studies, give matching criteria and number of exposed and unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6,7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6,7
Bias	9	Describe any efforts to address potential sources of bias	8
Study size	10	Explain how the study size was arrived at	5,6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7,8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7,8
		(b) Describe any methods used to examine subgroups and interactions	8
		(c) Explain how missing data were addressed	8
		(d) If applicable, explain how loss to follow-up was addressed	8
		(e) Describe any sensitivity analyses	8
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8
		(b) Give reasons for non-participation at each stage	8
		(c) Consider use of a flow diagram	20
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	15
		(b) Indicate number of participants with missing data for each variable of interest	NA
		(c) Summarise follow-up time (eg, average and total amount)	9
Outcome data	15*	Report numbers of outcome events or summary measures over time	9,10,16,17,18

1	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9,10,11
2			(b) Report category boundaries when continuous variables were categorized	NA
3			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	9,10
4	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	11
5	<b>Discussion</b>			
6	Key results	18	Summarise key results with reference to study objectives	11
7	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	13
8	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12,13,14
9	Generalisability	21	Discuss the generalisability (external validity) of the study results	14
10	<b>Other information</b>			
11	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	1

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

# BMJ Open

## Association between incident falls and subsequent fractures in patients attending the Fracture Liaison Service after an index fracture: a 3-year prospective observational cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-058983.R2
Article Type:	Original research
Date Submitted by the Author:	23-Jun-2022
Complete List of Authors:	Vranken, Lisanne; VieCuri Medical Centre, Department of Internal Medicine; Maastricht University Medical Centre+, Department of Internal Medicine, Research School NUTRIM Wyers, Caroline; VieCuri Medical Centre, Department of Internal Medicine; Maastricht University Medical Centre+, Department of Internal Medicine, Research School NUTRIM Van der Velde, R.Y.; VieCuri Medical Centre, Department of Internal Medicine; Maastricht University Medical Centre+, Department of Internal Medicine, Research School NUTRIM Janzing, Heinrich M. J.; VieCuri Medical Centre, Department of Surgery Kaarsemakers, S.; VieCuri Medical Centre, Department of Orthopedic Surgery Driessen, Johanna; Maastricht University Medical Centre+, Department of Clinical Pharmacy and Toxicology; Maastricht University, Department of Clinical Pharmacy and Toxicology Eisman, John; Garvan Institute of Medical Research, Osteoporosis and bone biology; The University of Notre Dame Australia, School of Medicine Sydney Center, Jacqueline; Garvan Institute of Medical Research, Osteoporosis and bone biology; UNSW, School of Population Health Nguyen, T.V.; Garvan Institute of Medical Research; UNSW, School of Population, Faculty of Medicine Tran, Thach; Garvan Institute of Medical Research, Bone Biology Division Bliuc, Dana; Garvan Institute of Medical Research, Bone and Mineral Research Program Geusens, Piet; Maastricht Universitair Medisch Centrum+, Department of Internal Medicine, Subdivision Reumatology; Maastricht University, CAPHRI School for Public Health and Primary Care van den Bergh, Joop; VieCuri Medical Centre, Department of Internal Medicine; Maastricht University Medical Centre+, Department of Internal Medicine, Research School NUTRIM
<b>Primary Subject Heading</b>:	Epidemiology
Secondary Subject Heading:	Rheumatology, Geriatric medicine, General practice / Family practice
Keywords:	INTERNAL MEDICINE, Orthopaedic & trauma surgery < SURGERY,

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

	GENERAL MEDICINE (see Internal Medicine)

SCHOLARONE™  
Manuscripts

BMJ Open: first published as 10.1136/bmjopen-2021-058983 on 27 July 2022. Downloaded from <http://bmjopen.bmj.com/> on June 27, 2024 by guest. Protected by copyright.



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Association between incident falls and subsequent fractures in patients attending**  
4 **the Fracture Liaison Service after an index fracture: a 3-year prospective**  
5 **observational cohort study.**  
6  
7  
8  
9

10  
11  
12 L. Vranken <sup>1,2,3</sup>, C.E. Wyers <sup>1,2,3</sup>, R.Y. Van der Velde <sup>1,2,3</sup>, H.M.J. Janzing <sup>4</sup>, S. Kaarsemakers <sup>5</sup>,  
13  
14 J.H.M. Driessen <sup>6,7</sup>, J.A. Eisman <sup>8,9,10</sup>, J.R. Center <sup>8,10</sup>, T.V. Nguyen <sup>8,10,11</sup>, T. Tran <sup>8</sup>, D. Bliuc <sup>8</sup>,  
15  
16 P.P.M.M. Geusens <sup>12,13,14</sup>, J.P. Van den Bergh <sup>1,2,3,\*</sup>  
17  
18  
19  
20  
21

- 22 1. Department of Internal Medicine, VieCuri Medical Center, Venlo, The Netherlands  
23  
24 2. Department of Internal Medicine, Maastricht University Medical Center +,  
25  
26 Maastricht, The Netherlands  
27  
28 3. NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht  
29  
30 University, Maastricht, The Netherlands  
31  
32 4. Department of Surgery, VieCuri Medical Center, Venlo, The Netherlands  
33  
34 5. Department of Orthopedic Surgery, VieCuri Medical Center, Venlo, The Netherlands  
35  
36 6. Department of Clinical Pharmacy and Toxicology, NUTRIM School of Nutrition and  
37  
38 Translational Research in Metabolism, CARIM School for Cardiovascular Disease,  
39  
40 Maastricht University Medical Center +, P.O. Box 5800, 6202 AZ Maastricht, The  
41  
42 Netherlands  
43  
44 7. Department of Clinical Pharmacy and Toxicology, CAPHRI School for Public Health  
45  
46 and Primary Care, Maastricht University, Maastricht, The Netherlands  
47  
48 8. Osteoporosis and Bone Biology, Garvan Institute of Medical Research, Sydney,  
49  
50 Australia  
51  
52 9. School of Medicine Sydney, University of Notre Dame Australia, Sydney, Australia  
53  
54  
55  
56  
57  
58  
59  
60 10. School of Population Health, Faculty of Medicine, UNSW Sydney, Sydney, Australia

- 1  
2  
3 11. School of Biomedical Engineering, University of Technology Sydney, Sydney,  
4  
5 Australia  
6  
7  
8 12. CAPHRI School for Public Health and Primary Care, Maastricht University,  
9  
10 Maastricht, The Netherlands  
11  
12 13. Department of Internal Medicine, Subdivision Rheumatology, Maastricht University  
13  
14 Medical Center +, Maastricht, The Netherlands  
15  
16  
17 14. Faculty of Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium  
18  
19 \* Corresponding author  
20  
21  
22  
23  
24  
25

### Corresponding author

26 Name: J.P. van den Bergh

27  
28 Postal address: Tegelseweg 210, 5912 BL Venlo

29  
30 E-mail: [jvdbergh@viecuri.nl](mailto:jvdbergh@viecuri.nl)

31  
32 Telephone: 0031-773205555

33  
34 Fax numbers: 0031-773206279  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

**Objectives:** To evaluate the risk of subsequent fractures in patients who attended the Fracture Liaison Service (FLS), with and without incident falls after the index fracture.

**Design:** A 3-year prospective observational cohort study.

**Setting:** An outpatient FLS in The Netherlands.

**Participants:** Patients aged 50+ years with a recent clinical fracture.

**Outcome measures:** Incident falls and subsequent fractures.

**Results:** The study included 488 patients (71.9% women, mean age  $64.6 \pm 8.6$  years). During the 3-year follow-up, 959 falls had been ascertained in 296 (60.7%) patients (*i.e.*, fallers), and 60 subsequent fractures were ascertained in 53 (10.9%) patients. Of the fractures, 47 (78.3%) were fall-related, of which 25 (53.2%) were sustained at the first fall incident at a median of 34 weeks. An incident fall was associated with an approximately 9-fold (hazard ratio 8.6, 95% confidence interval 3.1 to 23.8) increase in the risk of subsequent fractures.

**Conclusion:** These data suggest that subsequent fractures among patients on treatment prescribed in a FLS setting are common, and that an incident fall is a strong predictor of subsequent fracture risk. Immediate attention for fall risk could be beneficial in an FLS model of care.

**Trial registration:** Registration number NL45707.072.13

## Strengths and limitations

- Although this is one of the largest prospective studies in a FLS population focusing on the incidence of falls after an index fracture, the number of patients is modest, and the number of subsequent fractures relatively small.



- Data on falls were collected prospectively using fall diaries, but no procedures were in place to validate self-reported falls.
- No information was available on falls between the index fracture and enrollment in the study.
- Relatively healthy patients participated in the study, which may have resulted in an underestimation of incident falls and subsequent fractures.

For peer review only

## 1 Introduction

2 Patients with a recent fracture have a high imminent risk of subsequent fractures  
3 as shown after most fractures (1-6), and a high risk of subsequent falls, as shown after a  
4 recent hip fracture (7-11). The Fracture Liaison Service (FLS) is considered the most  
5 effective organizational approach for secondary fracture prevention in patients after the  
6 age of 50 years with a recent fracture.

7 Most fractures are caused by a fall, but most falls do not result in a fracture  
8 (12,13). Falls are a major contributing factor to the occurrence of fractures, independent  
9 and additive to the risk attributable to age and bone mineral density (BMD) (14-17).  
10 Guidelines on the FLS therefore recommend fall prevention and prescription of anti-  
11 osteoporosis medication (AOM) in high risk patients (18-22). However, it is not well  
12 known to what extent the imminent risk of subsequent fractures after an index fracture  
13 can be attributed to incident falls. We hypothesized that the risk of subsequent fractures  
14 would be substantially higher in patients with falls after a recent fracture than in those  
15 without falls. The aim of this study was therefore to evaluate the incidence of falls and  
16 subsequent fractures, and the risk of subsequent fractures in those with and without  
17 falls after a recent index fracture in patients who attend the FLS.

## 18 Methods

### 19 *Study population and design*

20 A 3-year prospective observational cohort study was conducted including 500  
21 consecutive patients aged between 50 and 90 years with a recent, radiologically  
22 confirmed clinical vertebral or non-vertebral low-trauma fracture, and who were willing  
23 and able to participate. Patients were recruited at the FLS in VieCuri Medical Center,  
24 Venlo, The Netherlands.

1  
2 26 Low-trauma fractures were defined as fractures that resulted from a fall from standing  
3  
4 27 height or less. Excluded were non-Caucasian patients, patients with bone metastasis,  
5  
6 28 failure of prosthesis or osteomyelitis, and patients with cognitive impairment.

8  
9 29 According to standard care, a nurse specialized in osteoporosis invited all  
10  
11 30 patients aged 50 year and older, who visited the emergency department because of a  
12  
13 31 recent clinical vertebral or non-vertebral fracture, to the FLS. All patients who  
14  
15 32 responded and agreed to be evaluated were scheduled an appointment for fracture risk  
16  
17 33 evaluation. Fracture risk evaluation included a detailed questionnaire for evaluation of  
18  
19 34 risk factors for fractures and falls, including medical history and medication use. This  
20  
21 35 questionnaire was based on the Dutch guidelines on osteoporosis and fracture  
22  
23 36 prevention, and prevention of falls in the elderly (23,24). Also, height and weight were  
24  
25 37 measured, a bone mineral density (BMD) measurement with dual-energy X-ray  
26  
27 38 absorptiometry (DXA) of the lumbar spine, total hip, and femoral neck, with vertebral  
28  
29 39 fracture assessment (VFA) was performed, and a blood sample was collected to detect  
30  
31 40 contributors to secondary osteoporosis and metabolic bone disease (25). According to  
32  
33 41 the Dutch osteoporosis guideline (23), AOM was started in patients with osteoporosis or  
34  
35 42 having at least one moderate to severe prevalent vertebral fracture according to Genant  
36  
37 43 et al. (26). Bisphosphonates and denosumab were first-choice treatments. Teriparatide  
38  
39 44 was restricted to patients already on another AOM with at least 3 fractures, of which 2  
40  
41 45 were vertebral fractures.

42  
43 46 The study protocol (registration number NL45707.072.13) was approved by an  
44  
45 47 independent Medical Ethics Committee and complied with the Declaration of Helsinki.  
46  
47 48 All patients gave written informed consent prior to participation.

48  
49 49

50 ***Falls and subsequent fractures***

1  
2 51 During the 3-year follow-up, patients were requested to record falls weekly in a  
3  
4 52 fall diary. Fall registration started at the beginning of the study, mean  $3.5 \pm 1.0$  months  
5  
6 53 after the index fracture. A fall was defined as an unintentional change in position  
7  
8  
9 54 resulting in coming to rest on the ground or other lower level (27). Patients were asked  
10  
11 55 to return their fall diaries by mail at 3 and 6 months, and during the study visit at 1, 2  
12  
13 56 and 3 year of follow-up. They were contacted by telephone if the fall diary was not  
14  
15  
16 57 received or incomplete. Patients were categorized as those with at least one incident fall  
17  
18 58 (*i.e.*, faller) or without an incident fall (*i.e.*, non-faller) during follow-up.  
19

20  
21 59 When patients recorded a fall in their diary, they were also asked to record  
22  
23 60 whether or not they sustained a subsequent clinical fracture as a direct result of the fall.  
24  
25 61 Additionally, at 1-, 2-, and 3-year follow-up, patients had to complete a detailed  
26  
27 62 questionnaire, including a question on whether they sustained a fracture due to another  
28  
29 63 trauma than a fall or without an overt trauma. All subsequent fractures were  
30  
31 64 radiologically confirmed according to radiology reports in the electronic patient records.  
32  
33 65 Since no imaging of the spine was performed at the end of the study, all reported  
34  
35 66 vertebral fractures were symptomatic, clinical vertebral fractures. A distinction was  
36  
37 67 made between subsequent fractures that were directly caused by a fall (*i.e.*, fall-related  
38  
39 68 fractures), and those that occurred without an overt trauma or were the result of  
40  
41 69 another trauma than a fall (*i.e.*, non-fall-related fractures).  
42  
43  
44  
45  
46  
47  
48

## 49 71 **Data analysis**

50  
51 72 Baseline characteristics were compared between fallers and non-fallers, and between  
52  
53 73 patients with and without subsequent fractures using the Student's t test or Wilcoxon  
54  
55 74 test for continuous variables, and Chi-squared or Fisher's exact test for categorical  
56  
57 75 variables where appropriate. The incidence rate of falls and subsequent fractures per  
58  
59  
60 76 100 person-years was estimated at 3 and 6 months and 1, 2 and 3 year follow-up,

1  
2 77 assuming a Poisson distribution. Kaplan Meier curves were made for incident falls and  
3  
4 78 subsequent fractures, in which patients were included once, and only the first incident  
5  
6 79 fall or subsequent fracture was included. Cox proportional hazards regression was used  
7  
8  
9 80 to determine the association between incident falls and subsequent fractures, yielding  
10  
11 81 hazard ratios (HR) and 95% confidence intervals (CI). Proportional hazard assumptions  
12  
13 82 were not violated. Follow-up time was determined by the first subsequent fracture, lost-  
14  
15 83 to-follow-up or the end of the study, whatever occurred first. All analyses were adjusted  
16  
17 84 for the predefined covariates, including age, gender, index fracture type (major or hip  
18  
19 85 versus any other fracture), BMD (lowest measured at lumbar spine, total hip, femoral  
20  
21 86 neck), prevalent vertebral fractures (moderate or severe versus mild or no prevalent  
22  
23 87 vertebral fractures). A p-value < 0.05 was considered statistically significant.

24  
25  
26  
27 88 Two sensitivity analyses were planned; (i) excluding patients with index and  
28  
29 89 subsequent finger or toe fractures, and (ii) by classifying patients with a non-fall-related  
30  
31 90 subsequent fracture as non-faller, even if they fell at another time during follow-up.  
32  
33  
34  
35  
36

### 37 92 ***Patient and public involvement***

38  
39 93 Patients or members of the public were not involved in the design, or conduct, or  
40  
41 94 reporting, or dissemination plans of the research.  
42  
43  
44  
45

## 46 96 **Results**

### 47 97 ***Study population***

48  
49 98 Among 1220 patients approached from the FLS, 1011 patients met the study  
50  
51 99 criteria. Of the 1011 patients, 511 were not willing or able to participate in the study,  
52  
53 100 and after excluding 12 patients with missing fall data, ultimately 488 patients were  
54  
55 101 available for analysis (**Supplementary Figure 1**) of whom 34 (7.0%) patients had  
56  
57  
58  
59  
60

1  
2 102 incomplete follow-up data on incident falls (5 patients died, 8 withdrew consent, 21 had  
3  
4 103 incomplete fall registration).

5  
6 104 The mean time between the index fracture and FLS visit at which patients were  
7  
8  
9 105 included for this study was  $3.9 \pm 1.1$  months for patients with a hip fracture and  $3.5 \pm 1.0$   
10  
11 106 months for patients with other fractures. Baseline characteristics of the 488 study  
12  
13 107 participants are presented in **Table 1**. Mean age was  $64.6 \pm 8.6$  year and 71.9% of the  
14  
15 108 patients were women. In 86.5% of patients, the index fracture was caused by a fall, and  
16  
17 109 28.5% of patients had at least one other fall in the year before the start of the study. At  
18  
19 110 baseline, 21.9% of patients were diagnosed with osteoporosis, 51.1% with osteopenia,  
20  
21 111 and 27.1% had a normal BMD. Lowest BMD was measured at the femoral neck in 470  
22  
23 112 participants, at the total hip in 3 participants, and at the lumber spine in 15 participants.  
24  
25 113 Moderate to severe (i.e., grade 2-3) prevalent vertebral fractures were present in 14.3%  
26  
27 114 of patients. AOM was prescribed in 34.2% of patients (8 (1.6%) were already using AOM,  
28  
29 115 and 159 (32.6%) started using AOM at baseline visit).

30  
31  
32  
33  
34 116 Compared to eligible FLS attenders, who were not willing or able to participate in  
35  
36 117 our study, patients included in our study were younger, had fewer major or hip  
37  
38 118 fractures, had a higher BMD, and a lower proportion had prevalent vertebral fractures  
39  
40 119 (see **Supplementary Table 1**).

41  
42  
43  
44 120

## 45 46 121 **Falls**

47  
48  
49 122 During a median follow-up of 3 years (range 0.1 to 3.0), 296 (60.7%) patients  
50  
51 123 recorded 959 falls, corresponding to 68.6 falls per 100 person-years. The cumulative fall  
52  
53 124 incidences and incidence rates per 100 person-years at 3 and 6 months, and at 1, 2 and 3  
54  
55 125 year follow-up are presented in **Figure 1**. Of the 296 patients with at least one fall, 115  
56  
57 126 (38.9%) had one fall and 181 (61.1%) had two or more falls (up to 39 falls in one  
58  
59 127 patient).

1  
2 128 A first fall was recorded by 189/488 (38.7%) patients during the first year of  
3  
4 129 follow-up, by 56/299 (18.7%) during the second, and by 51/243 (21.0%) during the  
5  
6 130 third year of follow-up. The median time to the first fall was 34 (range 1-156) weeks. Of  
7  
8  
9 131 the 959 falls, 47 (4.9%) resulted in a subsequent fall-related fracture.

10  
11 132 There were no significant differences in baseline characteristics between patients  
12  
13 133 with and without a fall during the 3-year follow-up, except for that a higher proportion  
14  
15 134 of patients with incident falls reported at least one fall in the year before the start of the  
16  
17 135 study (34.5% vs. 19.3%,  $p < 0.001$ ) (see **Table 1**). There were no significant differences  
18  
19 136 in baseline characteristics between patients with one fall and those with multiple falls  
20  
21 137 (data not shown).  
22  
23  
24  
25  
26  
27

### 28 139 ***Subsequent fractures***

29  
30 140 In total, 53 (10.9%) patients recorded 60 subsequent fractures, corresponding to  
31  
32 141 4.29 subsequent fractures per 100 person-years. The cumulative subsequent fracture  
33  
34 142 incidences and incidence rates (per 100-person years) at 3 and 6 months, and at 1, 2 and  
35  
36 143 3 year follow-up are presented in **Figure 2**. Of all subsequent fractures, 47 (78.3%) were  
37  
38 144 fall-related, and 13 (21.7%) were non-fall-related. Fall-related subsequent fracture sites  
39  
40 145 were: radius and ulna (n=9), tibia and fibula (n=8), proximal femur (n=4), metatarsal  
41  
42 146 (n=4), hand phalanx (n=4), symptomatic vertebra (n=3), proximal humerus (n=3),  
43  
44 147 clavicle (n=3), costal bones (n=2), scapula (n=2), pelvic bone (n=1), metacarpal (n=1),  
45  
46 148 tarsal (n=1), patella (n=1), and foot phalanx (n=1), whereas subsequent non-fall-related  
47  
48 149 fractures sites were: symptomatic vertebral (n=5), metatarsal (n=2), foot phalanx (n=5),  
49  
50 150 and hand phalanx (n=1). Half (53.2%) of all fall-related subsequent fractures were  
51  
52 151 sustained at the first fall.  
53  
54  
55  
56  
57

58 152 Baseline characteristics for patients with and without subsequent fractures are  
59  
60 153 presented in **Table 1**.

1  
2 154 Of the 296 patients with at least one fall, 41 (13.9%) had 46 fall-related subsequent  
3  
4 155 fractures, 7 (2.4%) had 7 non-fall-related subsequent fractures, and 1 (0.3%) had 1 fall-  
5  
6 156 and 1 non-fall-related subsequent fracture. Of the 192 patients without a fall, 4 (2.1%)  
7  
8  
9 157 had 5 non-fall-related subsequent fractures. Of note, the risk of subsequent fractures was  
10  
11 158 higher in patients with at least one fall than in those without a fall (adjusted HR (95% CI):  
12  
13 159 8.6 (3.1-23.8); cumulative incidence: 16.6% versus 2.1%) (**Figure 3 and Table 2**).  
14  
15  
16 160 Results were similar when femoral neck BMD instead of the lowest BMD was used for  
17  
18 161 adjustments (adjusted HR (95% CI): 8.3 (3.0-23.0)). Additionally, subsequent fracture  
19  
20 162 risk was higher in patients with moderate or severe prevalent vertebral fractures than in  
21  
22  
23 163 those with no or mild prevalent vertebral fractures (adjusted HR (95% CI): 3.9 (2.1-7.3);  
24  
25 164 cumulative incidence: 24.3% versus 8.6%) (**Table 2**).

26  
27  
28 165 The association between falls and subsequent fractures remained significant in  
29  
30 166 sensitivity analyses (i) excluding patients with index and subsequent finger and toe  
31  
32 167 fractures (adjusted HR (95% CI): 8.2 (2.5-26.6)), and (ii) by classifying patients with a  
33  
34 168 non-fall-related subsequent fracture as non-faller (adjusted HR (95% CI): 2.9 (1.5-5.6)).  
35  
36

37 169

## 39 170 **Discussion**

40  
41  
42 171 In this 3-year prospective observational cohort study in patients aged 50+ years  
43  
44 172 with a recent clinical fracture, treated according to current Dutch osteoporosis  
45  
46 173 guidelines at a FLS, 60.7% of patients had at least one fall, and 10.9% had at least one  
47  
48 174 subsequent fracture. The majority (78.3%) of subsequent fractures was caused by a fall,  
49  
50  
51 175 and of all fall-related subsequent fractures, 53.2% occurred at the first fall. Subsequent  
52  
53 176 fracture risk was nine-fold higher in fallers than in non-fallers.

54  
55  
56 177 Literature reporting fall incidence in fracture patients is limited. Comparable to  
57  
58 178 our results, Van Helden et al. (28) reported a 3-month fall incidence of 15% in patients  
59  
60 179 with a recent fracture at a FLS, and Matsumoto et al. (29) reported a 1-year fall



1  
2 180 incidence of 40% in ambulatory patients with a recent fracture. Various other studies  
3  
4 181 included older, hip fracture patients and reported higher one year fall incidences up to  
5  
6 182 55% (7-11), except for the study from Yeh et al. that reported a lower 1-year fall  
7  
8  
9 183 incidence (31%) (30). Higher fall incidences in hip fracture studies can partially be  
10  
11 184 explained by the older study population. Unfortunately, other fall risk factors cannot be  
12  
13  
14 185 compared. An explanation for the lower fall incidence in the study by Yeh et al. may be  
15  
16 186 that information on the occurrence of falls was provided by patients and family  
17  
18 187 caregivers, which may have resulted in under registration of falls.  
19

20  
21 188 A comparison between the fall incidence in our study and that in the general  
22  
23 189 population is difficult to make, because population-based studies were conducted in a  
24  
25 190 65+ aged, community-dwelling population, whereas approximately 50% of our study  
26  
27 191 population was <65 years old. The proportion of community-dwelling people aged 65+  
28  
29 192 years sustaining at least one fall over a 1-year period ranged from 28 to 35% (31-33),  
30  
31 193 with an increasing incidence with increasing age (34). The 1-year fall incidence reported  
32  
33 194 is our study is comparable to that in an older (65+ aged) population, and therefore  
34  
35 195 relatively high. However, in contrast to what has been reported in literature, we found  
36  
37 196 no higher 3-year fall incidence with increasing age. An explanation for this could be that,  
38  
39 197 especially in the older age group, relatively more healthy patients participated in our  
40  
41 198 study, resulting in a lower fall incidence in older age group. Another explanation could  
42  
43 199 be that patients aged 50-65 years are more physically active, and therefore fall more  
44  
45 200 often.  
46  
47  
48  
49

50  
51 201 Compared to our results, previously published FLS studies reported lower  
52  
53 202 (35,36), similar (28,37,38), and higher (39,40) subsequent fracture rates. Differences  
54  
55 203 can be explained by differences in patient selection. Studies that included older patients  
56  
57 204 (39) and patients with more severe fractures (40) reported higher subsequent fracture  
58  
59  
60

1  
2 205 rates, whereas studies that excluded hand and foot index and subsequent fractures (35)  
3  
4 206 or frail patients reported lower rates (36).  
5  
6 207 In 2010, the Dutch population consisted of approximately 6,000,000 people aged 50+  
7  
8 208 years, of whom 119,419 sustained a fracture that year (41), corresponding to a  
9  
10 209 calculated annual fracture incidence of 2.0% in the general Dutch 50+ population.  
11  
12 210 Compared to the general Dutch 50+ population, the fracture incidence was more than 2  
13  
14 211 times higher in our study, even in the 3rd year of follow-up. In our study, fracture  
15  
16 212 incidence remained high despite treatment according to the current osteoporosis  
17  
18 213 guideline, raising the question of what more can be done to prevent subsequent  
19  
20 214 fractures. Even though conflicting results have been published about the effect of fall  
21  
22 215 prevention strategies on subsequent fracture (42), we hypothesize that fall  
23  
24 216 interventions could be effective in patients at highest risk, namely those with a recent  
25  
26 217 fracture at risk of falling. Furthermore, according to literature, recurrent fallers have an  
27  
28 218 almost fourfold increased odds of sustaining a fall-related fracture compared to  
29  
30 219 individuals with a single fall (43). However, we found that the majority of subsequent  
31  
32 220 fall-related fractures occur at the first fall after the index fracture, with a median time to  
33  
34 221 the first fall of 34 weeks. Interestingly, fall incidence was higher in the first year of  
35  
36 222 follow-up compared to the second and third year. This may indicate an imminent fall  
37  
38 223 risk, which may attribute to the imminent subsequent fracture risk after an index  
39  
40 224 fracture (1-6). This implies that the FLS patients with a high fall risk should be identified  
41  
42 225 immediately, because there is a small window of opportunity to prevent falls and fall-  
43  
44 226 related subsequent fractures.  
45  
46  
47  
48  
49  
50  
51  
52

53 227 Remarkably, in contrast to previous studies indicating that imminent fracture  
54  
55 228 risk that was highest in the first year after an index fracture (44,45), there was a linear  
56  
57 229 subsequent fracture incidence during 3-year follow-up in this study. An explanation for  
58  
59 230 the linear subsequent fracture incidence may be the relatively healthy patients who  
60

1  
2 231 agreed to participate in our study. Compared to non-attenders, they were younger, and a  
3  
4 232 lower proportion had a major baseline fracture, a prevalent vertebral fracture, and  
5  
6 233 osteoporosis, and if indicated, were more likely to receive AOM. Importantly, in addition  
7  
8 234 to falls, moderate to severe prevalent vertebral fractures at baseline were associated  
9  
10 235 with subsequent fractures, even though anti-osteoporosis medication had been  
11  
12 236 prescribed to these patients according to the current Dutch osteoporosis guideline.  
13  
14  
15

16 237         This study has several limitations. Although, this is one of the largest prospective  
17  
18 238 studies in a FLS population focusing on the incidence of falls after an index fracture, the  
19  
20 239 number of patients is modest, and the number of subsequent fractures relatively low.  
21  
22  
23 240 Therefore, the association between falls and fall-related, and non-fall-related  
24  
25 241 subsequent fractures could not be analyzed separately. A fall 'not-resulting-in-a-  
26  
27 242 subsequent-fracture' might indicate frailty of patients, and might be different from those  
28  
29 243 falls that directly resulted in a subsequent fracture. Future studies are needed to  
30  
31 244 investigate this difference. Finally, because of small numbers, subgroup analyses should  
32  
33 245 not be performed. Furthermore, data on falls were collected prospectively using fall  
34  
35 246 diaries that had to be returned at 3 and 6 months, and 1, 2, and 3 year. However, no  
36  
37 247 procedures were in place to validate self-reported falls, and it is possible that recall bias,  
38  
39 248 could have led to underregistration of falls. Moreover, no information was available on  
40  
41 249 falls between the index fracture and enrollment in the study. Finally, relatively healthy  
42  
43 250 patients participated in the study. Compared to non-attenders, they were younger, a  
44  
45 251 lower proportion had a major baseline fracture, a prevalent vertebral fracture, and  
46  
47 252 osteoporosis. The proportion of patients with a fall and subsequent fractures could be  
48  
49 253 expected to be even higher in the total FLS population.  
50  
51  
52  
53  
54

55 254         In conclusion, in this 3-year prospective observational cohort study in FLS  
56  
57 255 patients, subsequent fracture incidence was high despite being prescribed anti-  
58  
59 256 osteoporosis medications according to the current Dutch osteoporosis guideline.  
60

1  
2 257 Subsequent fracture risk was nine-fold higher in fallers than in non-fallers, and the  
3  
4 258 majority of fall-related subsequent fractures occurred at the first fall at a median time of  
5  
6 259 34 weeks. These findings emphasize that immediate attention for fall risk reduction  
7  
8 260 could be beneficial in FLS care. Various risk factors, including comorbidities, medication  
9  
10 261 use, polypharmacy and alcohol use among others, contribute to patient's fall risk and  
11  
12 262 further research is needed to determine predictors for falls to identify patients at  
13  
14 263 highest risk of falling.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Figures and tables

**Table 1.** Baseline characteristics of 488 participants stratified by incident fall and subsequent fracture status.

	<b>Total population</b> (n=488)	<b>Non-fallers</b> (n=192)	<b>Fallers</b> (n=296)	<b>P-value</b>	<b>No subsequent fracture</b> (n=435)	<b>Subsequent fracture</b> (n=53)	<b>P-value</b>
<b>Age (years)</b>	64.6 ± 8.6	64.4 ± 8.0	64.8 ± 9.0	0.608	64.5 ± 8.8	65.3 ± 7.1	0.488
<b>Female gender</b>	351 (71.9)	130 (67.7)	221 (74.7)	0.095	308 (70.8)	43 (81.1)	0.114
<b>Baseline fracture</b>							
- Finger or toe	55 (11.3)	30 (15.6)	25 (8.4)	0.060	49 (11.3)	6 (11.3)	0.460
- Minor	303 (62.1)	109 (56.8)	194 (65.5)		270 (62.1)	33 (62.3)	
- Major	104 (21.3)	44 (22.9)	60 (20.3)		95 (21.8)	9 (17.0)	
- Hip	26 (5.3)	9 (4.7)	17 (5.7)		21 (4.8)	5 (9.4)	
- Fall-related *	422 (86.5)	164 (85.4)	258 (87.2)	0.582	378 (86.9)	44 (83.0)	0.436
<b>Fall previous year §</b>							
- 0	349 (71.5)	155 (80.7)	194 (65.5)	<0.001	315 (72.4)	34 (64.2)	0.208
- ≥ 1	139 (28.5)	37 (19.3)	102 (34.5)		120 (27.6)	19 (35.8)	
<b>BMI (kg/m<sup>2</sup>)</b>	27.7 ± 4.4	27.7 ± 4.4	27.7 ± 4.4	0.961	27.8 ± 4.4	26.9 ± 4.8	0.154
<b>BMD</b>							
- Normal BMD	132 (27.1)	54 (28.1)	78 (26.4)	0.906	123 (28.3)	9 (17.0)	0.081
- Osteopenia	249 (51.0)	97 (50.5)	152 (51.4)		222 (51.0)	27 (50.9)	
- Osteoporosis	107 (21.9)	41 (21.4)	66 (22.3)		90 (20.7)	17 (32.1)	
<b>Prevalent vertebral fracture #§</b>							
- None	356 (73.0)	139 (72.4)	217 (73.3)	0.572	328 (75.4)	28 (52.8)	<0.001
- Grade 1	62 (12.7)	22 (11.5)	40 (13.5)		54 (12.4)	8 (15.1)	
- Grade 2-3	70 (14.3)	31 (16.1)	39 (13.2)		53 (12.2)	17 (32.1)	
<b>Anti-osteoporosis treatment</b>	167 (34.2)	70 (36.5)	97 (32.8)	0.402	142 (32.6)	25 (47.2)	0.035

Continuous variables are shown in mean ± SD (standard deviation), categorical variables are shown as number of patients (%). \* Signifying that fracture was caused by a fall. § Fall resulting in baseline fracture not included. # According to Genant et al. \$ According to most severe prevalent vertebral fracture. Abbreviations: BMD, bone mineral density.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Predictor	Unit of comparison	Hazard ratio and 95% confidence interval	P-value
Gender	Women vs men	1.39 (0.68 - 2.83)	0.362
Age	+5 years	0.97 (0.82 - 1.13)	0.662
Index fracture	Major or hip vs all other	0.68 (0.35 - 1.33)	0.263
BMD	-0.12 g/cm <sup>2</sup>	1.30 (0.95 - 1.78)	0.101
Prevalent vertebral fracture	Yes vs no	3.88 (2.07 - 7.27)	<0.0001
Fall	Yes vs no	8.58 (3.09 - 23.8)	<0.0001

1  
2  
3 **Figure legends**  
4  
5

6 **Figure 1.** Cumulative incidence of falls stratified by gender.  
7

8 **Figure 2.** Cumulative incidence of subsequent fractures stratified by gender.  
9

10 **Figure 3.** Cumulative incidence of subsequent fractures stratified by fall status.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## Contributors

LV collected data, carried out data analysis and drafted the manuscript. CW and JB developed the study design and wrote the research protocol, collected data, and critically reviewed the manuscript. PG developed the study design and wrote the research protocol, and critically reviewed the manuscript. RV collected data and critically reviewed the manuscript. TN and TT assisted with data analysis and critically reviewed the manuscript. HJ, SK, JD, JA, JC and DB critically reviewed the manuscript. All authors approved the final version of the manuscript.

## Competing interest

Dr. Vranken, Dr. Wyers, Dr. Van der Velden, Dr. Janzing, Dr. Kaarsemakers, Dr. Driessen, Dr. Eisman, Dr. Tran, and Dr. Bliuc have nothing to disclose.

Dr. Center reports honoraria for educational talks from Amgen, part support for educational meetings from Amgen, and advisory board participation for Amgen and Bayer, outside the submitted work.

Dr. Nguyen reports honoraria for lectures sponsored from Merck, and participation as executive member Asia Pacific Consortium on Osteoporosis, outside the submitted work.

Dr. Geusens reports grants from Amgen, Pfizer, MSD, UCB, Abbott, Lilly, BMS, Novartis, Roche, and Will Pharma, and honoraria for lectures from Amgen and Lilly, outside the submitted work.

Dr. van den Bergh reports grants for lectures from UCB, and Amgen, outside the submitted work.

## Funding

This work was supported by the Weijerhorst Foundation, grand number not applicable. The Weijerhorst Foundation was not involved in conducting the study, analyzing the data or writing the manuscript.



### **Patient consent for publication**

Patient consent for publication was not required.

### **Ethics approval**

This study (protocol ID number NL45707.072.13) has been approved by the Independent Review Board Nijmegen (IRBN).

### **Data availability statement**

No additional data available.

## References

1. Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, De Laet C, Jonsson B. Fracture risk following an osteoporotic fracture. *Osteoporos Int*. 2003 Dec 23;15(3):175–9.
2. Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, Eisman J, Fujiwara S, Garnero P, Kroger H, McCloskey EV, Mellstrom D, Melton LJ, Pols H, Reeve J, Silman A, Tenenhouse A. A meta-analysis of previous fracture and subsequent fracture risk. *Bone*. 2004 Aug;35(2):375–82.
3. van Helden S, Cals J, Kessels F, Brink P, Dinant G-J, Geusens P. Risk of new clinical fractures within 2 years following a fracture. *Osteoporosis International*. 2006;17(3):348–54.
4. Center JR, Bliuc D, Nguyen TV, Eisman JA. Risk of Subsequent Fracture After Low-Trauma Fracture in Men and Women. *JAMA*. American Medical Association; 2007 Jan 24;297(4):387–94.
5. Briggs AM, Sun W, Miller LJ, Geelhoed E, Huska A, Inderjeeth CA. Hospitalisations, admission costs and re-fracture risk related to osteoporosis in Western Australia are substantial: a 10-year review. *Aust N Z J Public Health*. 2015 Dec;39(6):557–62.
6. Balasubramanian A, Zhang J, Chen L, Wenkert D, Daigle SG, Grauer A, Curtis JR. Risk of subsequent fracture after prior fracture among older women. *Osteoporos Int*. 2019 Jan;30(1):79–92.
7. McKee KJ, Orbell S, Austin CA, Bettridge R, Liddle BJ, Morgan K, Radley K. Fear of falling, falls efficacy, and health outcomes in older people following hip fracture. *Disabil Rehabil*. 2002 Apr 15;24(6):327–33.

- 1  
2  
3 8. Shumway-Cook A, Ciol MA, Gruber W, Robinson C. Incidence of and risk factors for  
4 falls following hip fracture in community-dwelling older adults. *Phys Ther.* 2005  
5 Jul;85(7):648–55.  
6  
7
- 8  
9  
10 9. Kristensen MT, Foss NB, Kehlet H. Timed “up & go” test as a predictor of falls  
11 within 6 months after hip fracture surgery. *Phys Ther.* 2007 Jan;87(1):24–30.  
12  
13
- 14 10. Berggren M, Stenvall M, Olofsson B, Gustafson Y. Evaluation of a fall-prevention  
15 program in older people after femoral neck fracture: a one-year follow-up.  
16 *Osteoporosis International.* 2008 Jun;19(6):801–9.  
17  
18
- 19 11. Lloyd BD, Williamson DA, Singh NA, Hansen RD, Diamond TH, Finnegan TP, Allen  
20 BJ, Grady JN, Stavrinos TM, Smith EUR, Diwan AD, Fiatarone Singh MA. Recurrent  
21 and injurious falls in the year following hip fracture: a prospective study of  
22 incidence and risk factors from the Sarcopenia and Hip Fracture study. *J. Gerontol.*  
23 *A Biol. Sci. Med. Sci.* 2009 May;64(5):599–609.  
24  
25
- 26 12. Masud T, Morris RO. Epidemiology of falls. *Age and Ageing.* 2001 Nov;30 Suppl  
27 4(suppl 4):3–7.  
28  
29
- 30 13. Morrison A, Fan T, Sen SS, Weisenfluh L. Epidemiology of falls and osteoporotic  
31 fractures: a systematic review. *Clinicoecon Outcomes Res.* Dove Press; 2013;5:9–  
32 18.  
33  
34
- 35 14. Geusens P, Autier P, Boonen S, Vanhoof J, Declerck K, Raus J. The relationship  
36 among history of falls, osteoporosis, and fractures in postmenopausal women.  
37 *Arch Phys Med Rehabil.* 2002 Jul;83(7):903–6.  
38  
39
- 40 15. Kaptoge S, Benevolenskaya LI, Bhalla AK, Cannata JB, Boonen S, Falch JA,  
41 Felsenberg D, Finn JD, Nuti R, Hozowski K, Lorenc R, Miazgowski T, Jajic I, Lyritis  
42 G, Masaryk P, Naves-Diaz M, Poor G, Reid DM, Scheidt-Nave C, Stepan JJ, Todd CJ,  
43 Weber K, Woolf AD, Roy DK, Lunt M, Pye SR, O'Neill TW, Silman AJ, Reeve J. Low  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 BMD is less predictive than reported falls for future limb fractures in women  
4  
5 across Europe: results from the European Prospective Osteoporosis Study. *Bone*.  
6  
7 2005 Mar;36(3):387–98.  
8  
9
- 10  
11 16. Harvey NC, Odén A, Orwoll E, Lapidus J, Kwok T, Karlsson MK, Rosengren BE,  
12  
13 Ljunggren O, Cooper C, McCloskey E, Kanis JA, Ohlsson C, Mellström D, Johansson  
14  
15 H. Falls Predict Fractures Independently of FRAX Probability: A Meta-Analysis of  
16  
17 the Osteoporotic Fractures in Men (MrOS) Study. *Journal of Bone and Mineral*  
18  
19 *Research*. John Wiley & Sons, Ltd; 2017 Dec 8;33(3):510–6.  
20  
21
- 22  
23 17. Leslie WD, Morin SN, Lix LM, Martineau P, Bryanton M, McCloskey EV, Johansson  
24  
25 H, Harvey NC, Kanis JA. Fracture prediction from self-reported falls in routine  
26  
27 clinical practice: a registry-based cohort study. *Osteoporos Int*. Springer London;  
28  
29 2019 Nov;30(11):2195–203.  
30  
31
- 32  
33 18. Eisman JA, Bogoch ER, Dell R, Harrington JT, McKinney RE Jr., McLellan A, Mitchell  
34  
35 PJ, Silverman S, Singleton R, Siris E, for the ASBMR Task Force on Secondary  
36  
37 Fracture Prevention. Making the first fracture the last fracture: ASBMR task force  
38  
39 report on secondary fracture prevention. *Journal of Bone and Mineral Research*.  
40  
41 Wiley Subscription Services, Inc., A Wiley Company; 2012 Jul 26;27(10):2039–46.  
42  
43
- 44  
45 19. Lems WF, Dreinhöfer KE, Bischoff-Ferrari H, Blauth M, Czerwinski E, da Silva J,  
46  
47 Herrera A, Hoffmeyer P, Kvien T, Maalouf G, Marsh D, Puget J, Puhl W, Poor G,  
48  
49 Rasch L, Roux C, Schüler S, Seriola B, Tarantino U, van Geel T, Woolf A, Wyers C,  
50  
51 Geusens P. EULAR/EFORT recommendations for management of patients older  
52  
53 than 50 years with a fragility fracture and prevention of subsequent fractures. *Ann*  
54  
55 *Rheum Dis*. 2016 Dec 22;:annrheumdis-2016-210289-10.  
56  
57
- 58  
59 20. IOF Fracture Working Group, Åkesson K, Marsh D, Mitchell PJ, McLellan AR,  
60  
Stenmark J, Pierroz DD, Kyer C, Cooper C. Capture the Fracture: a Best Practice

- 1  
2  
3 Framework and global campaign to break the fragility fracture cycle. *Osteoporos*  
4 *Int.* Springer London; 2013 Apr 16;24(8):2135–52.
- 5  
6  
7  
8 21. Dreinhöfer KE, Mitchell PJ, Bégué T, Cooper C, Costa ML, Falaschi P, Hertz K, Marsh  
9 D, Maggi S, Nana A, Palm H, Speerin R, Magaziner J, on behalf of: the Fragility  
10 Fracture Network (FFN), European Geriatric Medicine Society (EuGMS), European  
11 Federation of National Associations of Orthopaedics and Traumatology (EFORT),  
12 International Collaboration of Orthopaedic Nursing (ICON), International Geriatric  
13 Fracture Society (IGFS), International Osteoporosis Foundation (IOF). A global call  
14 to action to improve the care of people with fragility fractures. *Injury*. 2018  
15 Aug;49(8):1393–7.
- 16  
17  
18 22. Javaid MK, Sami A, Lems W, Mitchell P, Thomas T, Singer A, Speerin R, Fujita M,  
19 Pierroz DD, Åkesson K, Halbout P, Ferrari S, Cooper C. A patient-level key  
20 performance indicator set to measure the effectiveness of fracture liaison services  
21 and guide quality improvement: a position paper of the IOF Capture the Fracture  
22 Working Group, National Osteoporosis Foundation and Fragility Fracture Network.  
23 *Osteoporos Int.* 2020 Apr 8;4(5):e001806.
- 24  
25  
26 23. Werkgroep CBO, Richtlijn Osteoporose en Fractuurpreventie, derde herziening  
27 [Dutch]. (CBO, Utrecht, 2011).
- 28  
29 24. Richtlijn Preventie van valincidenten bij ouderen (2017) [Dutch].  
30 ([https://richtlijndatabase.nl/richtlijn/preventie\\_van\\_valincidenten\\_bij\\_ouderen](https://richtlijndatabase.nl/richtlijn/preventie_van_valincidenten_bij_ouderen/startpagina_-_preventie_van_valincidenten.html)  
31 /startpagina\_-\_preventie\_van\_valincidenten.html).
- 32  
33  
34 25. Bours SPG, van Geel TACM, Geusens PPMM, Janssen MJW, Janzing HMJ, Hoffland  
35 GA, Willems PC, van den Bergh JPW. Contributors to secondary osteoporosis and  
36 metabolic bone diseases in patients presenting with a clinical fracture. *The Journal*  
37 *of Clinical Endocrinology & Metabolism*. 2011 May;96(5):1360–7.
- 38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 26. Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a  
4 semiquantitative technique. *Journal of Bone and Mineral Research*. John Wiley and  
5 Sons and The American Society for Bone and Mineral Research (ASBMR); 1993  
6 Sep;8(9):1137–48.  
7
- 8  
9  
10  
11  
12 27. The prevention of falls in later life. A report of the Kellogg International Work  
13 Group on the Prevention of Falls by the Elderly. *Dan Med Bull*. 1987 Apr;34 Suppl  
14 4:1–24.  
15
- 16  
17  
18  
19 28. van Helden S, Wyers CE, Dagnelie PC, van Dongen MC, Willems G, Brink PR,  
20 Geusens PP. Risk of falling in patients with a recent fracture. *BMC Musculoskeletal*  
21 *Disorders*. BioMed Central; 2007 Jun 28;8(1):348.  
22
- 23  
24  
25  
26 29. Matsumoto H, Makabe T, Morita T, Ikuhara K, Kajigase A, Okamoto Y, Ashikawa E,  
27 Kobayashi E, Hagino H. Accelerometry-based gait analysis predicts falls among  
28 patients with a recent fracture who are ambulatory: a 1-year prospective study. *Int*  
29 *J Rehabil Res*. 2015 Jun;38(2):131–6.  
30
- 31  
32  
33  
34 30. Yeh H-F, Shao J-H, Li C-L, Wu C-C, Shyu Y-IL. Predictors of postoperative falls in the  
35 first and second postoperative years among older hip fracture patients. *J Clin Nurs*.  
36 3rd ed. 2017 Nov;26(21-22):3710–23.  
37
- 38  
39  
40  
41 31. Prudham D, Evans JG. Factors associated with falls in the elderly: a community  
42 study. *Age and Ageing*. 1981 Aug;10(3):141–6.  
43
- 44  
45  
46  
47 32. Campbell AJ, Reinken J, Allan BC, Martinez GS. Falls in old age: a study of frequency  
48 and related clinical factors. *Age and Ageing*. 1981 Nov;10(4):264–70.  
49
- 50  
51  
52  
53 33. Blake AJ, Morgan K, Bendall MJ, Dallosso H, Ebrahim SB, Arie TH, Fentem PH,  
54 Bassey EJ. Falls by elderly people at home: prevalence and associated factors. *Age*  
55 *and Ageing*. 1988 Nov;17(6):365–72.  
56  
57  
58  
59  
60

- 1  
2  
3 34. World Health Organization WHO. WHO Global Report on Falls Prevention in Older  
4 Age. 2017 Jan 6;;1–53.
- 5  
6  
7  
8 35. Eekman DA, van Helden SH, Huisman AM, Verhaar HJJ, Bultink IEM, Geusens PP,  
9 Lips P, Lems WF. Optimizing fracture prevention: the fracture liaison service, an  
10 observational study. *Osteoporos Int*. Springer London; 2013 Sep 13;25(2):701–9.
- 11  
12  
13  
14  
15 36. Lih A, Nandapalan H, Kim M, Yap C, Lee P, Ganda K, Seibel MJ. Targeted  
16 intervention reduces refracture rates in patients with incident non-vertebral  
17 osteoporotic fractures: a 4-year prospective controlled study. *Osteoporos Int*.  
18 Springer-Verlag; 2011 Mar;22(3):849–58.
- 19  
20  
21  
22  
23  
24 37. Van der Kallen J, Giles M, Cooper K, Gill K, Parker V, Tembo A, Major G, Ross L,  
25 Carter J. A fracture prevention service reduces further fractures two years after  
26 incident minimal trauma fracture. *Int J Rheum Dis*. John Wiley & Sons, Ltd  
27 (10.1111); 2014 Feb;17(2):195–203.
- 28  
29  
30  
31  
32  
33 38. Huntjens KM, van Geel TA, van Helden S, van den Bergh J, Willems P, Winkens B,  
34 Geusens PP, Brink PR. The role of the combination of bone and fall related risk  
35 factors on short-term subsequent fracture risk and mortality. *BMC Musculoskeletal*  
36 *Disorders*. BioMed Central; 2013 Apr 4;14(1):721.
- 37  
38  
39  
40  
41  
42 39. Sanli I, van Helden SH, Broeke Ten RHM, Geusens P, van den Bergh JPW, Brink PRG,  
43 Poeze M. The role of the Fracture Liaison Service (FLS) in subsequent fracture  
44 prevention in the extreme elderly. *Aging Clin Exp Res*. 2018 Oct 11;31(8):1105–11.
- 45  
46  
47  
48  
49  
50 40. Deloumeau A, Moltó A, Roux C, Briot K. Determinants of short term fracture risk in  
51 patients with a recent history of low-trauma non-vertebral fracture. *Bone*. 2017  
52 Dec;105:287–91.
- 53  
54  
55  
56  
57 41. Lötters FJB, van den Bergh JP, de Vries F, Rutten-van Mölken MPMH. Current and  
58 Future Incidence and Costs of Osteoporosis-Related Fractures in The Netherlands:  
59  
60

- 1  
2  
3 Combining Claims Data with BMD Measurements. *Calcified Tissue International*.  
4  
5 Springer US; 2016 Mar;98(3):235–43.  
6  
7  
8 42. Wang Q, Jiang X, Shen Y, Yao P, Chen J, Zhou Y, Gu Y, Qian Z, Cao X. Effectiveness of  
9  
10 exercise intervention on fall-related fractures in older adults: a systematic review  
11  
12 and meta-analysis of randomized controlled trials. *BMC Geriatr. BioMed Central*;  
13  
14 2020 Sep 4;20(1):322–11.  
15  
16  
17 43. Pluijm SMF, Smit JH, Tromp EAM, Stel VS, Deeg DJH, Bouter LM, Lips P. A risk  
18  
19 profile for identifying community-dwelling elderly with a high risk of recurrent  
20  
21 falling: results of a 3-year prospective study. *Osteoporosis International*.  
22  
23 2006;17(3):417–25.  
24  
25  
26 44. van Geel TACM, Huntjens KMB, van den Bergh JPW, Dinant G-J, Geusens PP. Timing  
27  
28 of Subsequent Fractures after an Initial Fracture. *Curr Osteoporos Rep*. 2010 Jun  
29  
30 18;8(3):118–22.  
31  
32  
33 45. van Geel TACM, van Helden S, Geusens PP, Winkens B, Dinant G-J. Clinical  
34  
35 subsequent fractures cluster in time after first fractures. *Ann Rheum Dis*. 2008 Jul  
36  
37 29;68(1):99–102.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60






Figure 1. Cumulative incidence of falls stratified by gender.






Figure 2. Cumulative incidence of subsequent fractures stratified by gender.



**Figure 3.** Cumulative incidence of subsequent fractures stratified by fall status.



**Supplementary Figure 1.** Patient selection. Abbreviations: HET, high-energy trauma fractures; Fx, fracture.

**Supplementary table 1.** Characteristics of 1011 FLS patients that participated and not-participated in this study.

	Participants (n=500)	Non-participants (n=511)	P-value
Age in years	64.6 ± 8.6	68.3 ± 9.8	<.001
Female sex	357 (71.4)	396 (77.5)	.026
Baseline fracture			
- Finger or toe	58 (11.6)	53 (10.4)	<.001
- Minor	311 (62.2)	259 (50.7)	
- Major	105 (21.0)	157 (30.7)	
- Hip	26 (5.2)	42 (8.2)	
- Fall-related *	431 (86.2)	441 (86.3)	.963
Fall previous year §			
- 0	356 (71.2)	359 (70.3)	.741
- ≥ 1	144 (28.8)	152 (29.7)	
- ≥ 2	72 (14.4)	87 (17.0)	.252
BMD			
- Normal BMD	135 (27.0)	90 (17.6)	<.001
- Osteopenia	255 (51.0)	258 (50.5)	
- Osteoporosis	110 (22.0)	163 (31.9)	
Prevalent vertebral fracture			
- None	366 (73.2)	349 (68.3)	.010
- Grade 1	63 (12.6)	53 (10.4)	
- Grade 2-3	71 (14.2)	109 (21.3)	
At least one fall past year	143 (29.3)	152 (29.9)	.704

Continues variables are presented as mean ± SD, categorical variables are presented as number of patients (%). § Fall resulting in baseline fracture not included. # According to Genant et al. § According to most severe prevalent vertebral fracture. Abbreviations: BMD, bone mineral density

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page No
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1,3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3,4
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	5,6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5,6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	5,6
		(b) For matched studies, give matching criteria and number of exposed and unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6,7
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6,7
Bias	9	Describe any efforts to address potential sources of bias	8
Study size	10	Explain how the study size was arrived at	5,6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7,8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7,8
		(b) Describe any methods used to examine subgroups and interactions	8
		(c) Explain how missing data were addressed	8
		(d) If applicable, explain how loss to follow-up was addressed	8
		(e) Describe any sensitivity analyses	8
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8
		(b) Give reasons for non-participation at each stage	8
		(c) Consider use of a flow diagram	20
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	15
		(b) Indicate number of participants with missing data for each variable of interest	NA
		(c) Summarise follow-up time (eg, average and total amount)	9
Outcome data	15*	Report numbers of outcome events or summary measures over time	9,10,16,17,18

1	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9,10,11
2			(b) Report category boundaries when continuous variables were categorized	NA
3			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	9,10
4	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	11
5	<b>Discussion</b>			
6	Key results	18	Summarise key results with reference to study objectives	11
7	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	13
8	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12,13,14
9	Generalisability	21	Discuss the generalisability (external validity) of the study results	14
10	<b>Other information</b>			
11	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	1

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.